Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Profile Name | CD274 positive |
| Gene Variant Detail | |
| Relevant Treatment Approaches | Atezolizumab Ipilimumab + Nivolumab Pembrolizumab |
| Molecular Profile | Indication/Tumor Type | Response Type | Relevant Treatment Approaches | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|---|
| CD274 positive | lung non-small cell carcinoma | sensitive | Pembrolizumab | Pembrolizumab | FDA approved - On Companion Diagnostic | Actionable | In a Phase II/III trial (KEYNOTE-010) that supported FDA approval, treatment with Keytruda (pembrolizumab) resulted in improved overall survival (10.4 months at 2mg/kg, 12.7 months at 10mg/kg, vs 8.5 months) compared to chemotherapy in previously treated non-small cell lung cancer patients with CD274 (PD-L1) expression in over 1% of tumor cells (PMID: 26712084, PMID: 27026676, PMID: 27718847; NCT01905657). | 26712084 27026676 27718847 detail... |
| CD274 positive | ovarian cancer | predicted - sensitive | JQ1 | Preclinical | Actionable | In a preclinical study, JQ1 suppressed CD274 (PD-L1) expression in human ovarian cancer cell lines in culture, and inhibited CD274 (PD-L1) expression in both immune cells and tumor cells in syngeneic mouse models of ovarian cancer, resulted in cytotoxic T Cell-dependent inhibition of tumor progression (PMID: 27626654). | 27626654 | |
| CD274 positive | gastric adenocarcinoma | sensitive | Pembrolizumab | Pembrolizumab | Phase I | Actionable | In a Phase Ib trial, Keytruda (pembrolizumab) treatment resulted in partial response in 22% (8/36) of patients with CD274 (PD-L1)-positive gastric or gastroesophageal junction adenocarcinoma (PMID: 27157491). | 27157491 |
| CD274 positive | gastroesophageal junction adenocarcinoma | sensitive | Pembrolizumab | Pembrolizumab | Phase I | Actionable | In a Phase Ib tiral, Keytruda (pembrolizumab) treatment resulted in partial response in 22% (8/36) of patients with CD274 (PD-L1)-positive gastric and gastroesophageal junction adenocarcinoma (PMID: 27157491). | 27157491 |
| CD274 positive | glioblastoma | conflicting | Pembrolizumab | Pembrolizumab | Phase Ib/II | Actionable | In a Phase Ib trial, Keytruda (pembrolizumab) treatment resulted in partial response in 4% (1/25), stable disease in 48% (12/25), a median progression free survival of 2.8 months, and a median overall survival of 14.4 months in patients with CD274 (PD-L1) positive, bevacizumab-naive recurrent glioblastoma (Neuro Oncol (2016) 18 (suppl 6): vi25-vi26.). | detail... |
| CD274 positive | fibrous histiocytoma | sensitive | Pembrolizumab | Pembrolizumab | Case Reports/Case Series | Actionable | In a Phase II trial, Keytruda (pembrolizumab) treatment resulted in 1 complete response and 1 partial response in 3 patients with CD274 (PD-L1)-positive undifferentiated pleomorphic sarcoma (malignant fibrous histiocytoma) (J Clin Oncol 35, no. 15_suppl (May 20, 2017) 11008; NCT02301039). | detail... |
| CD274 positive | osteosarcoma | sensitive | Pembrolizumab | Pembrolizumab | Case Reports/Case Series | Actionable | In a Phase II trial, Keytruda (pembrolizumab) treatment resulted in 1 partial response in 2 patients with CD274 (PD-L1)-positive osteosarcoma (J Clin Oncol 35, no. 15_suppl (May 20, 2017) 11008; NCT02301039). | detail... |
| CD274 positive | lung small cell carcinoma | sensitive | Pembrolizumab | Pembrolizumab | Phase I | Actionable | In a Phase Ib trial (KEYNOTE-028), Keytruda (pembrolizumab) treatment resulted in an objective response rate of 33% (8/24) in patients with lung small cell carcinoma expressing CD274 (PD-L1) in 1% or more of tumor or stromal cells by IHC, including one patient with a complete response and seven patients with a partial response (PMID: 28813164; NCT02054806). | 28813164 |
| CD274 positive | gastroesophageal junction adenocarcinoma | sensitive | Pembrolizumab | Pembrolizumab | Phase II | Actionable | In a Phase II trial (KEYNOTE-059) that supported FDA approval, Keytruda (pembrolizumab) treatment resulted in an objective response rate of 15.5% (23/148, complete response 3, partial response 20) with a median response duration of 16.3 months in patients with CD274 (PD-L1)-positive (CPS >=1) gastric cancer or gastroesophageal junction adenocarcinoma (PMID: 29543932; NCT02335411). | 29543932 |
| CD274 positive | transitional cell carcinoma | predicted - sensitive | Durvalumab | Phase Ib/II | Actionable | In a Phase I/II trial, treatment with Imfinzi (durvalumab) resulted in an overall response rate (ORR) of 17.8% (34/191) in advanced urothelial carcinoma patients with an ORR of 27.6% (27/98) in patients with high PD-L1 (CD274) expression and 5.1% (4/79) in patients with low or negative PD-L1 (CD274), and similar complete response rates between the two groups (PMID: 28817753; NCT01693562). | 28817753 | |
| CD274 positive | ovarian cancer | sensitive | Pembrolizumab | Pembrolizumab | Phase I | Actionable | In a Phase Ib trial (KEYNOTE-028), Keytruda (pembrolizumab) treatment resulted in an objective response rate of 11.5% (3/26, 1 complete response, 2 partial response) and stable disease in 26.9% (7/26) of patients with CD274 (PD-L1)-positive ovarian cancer, with a median progression-free survival of 1.9 months and a median overall survival of 13.8 months (PMID: 29095678, PMID: 30522700; NCT02054806). | 29095678 30522700 |
| CD274 positive | malignant spindle cell melanoma | predicted - sensitive | Pembrolizumab | Pembrolizumab | Clinical Study - Cohort | Actionable | In a retrospective analysis, PD-1 blockade therapies including Keytruda (pembrolizumab), Opdivo (nivolumab), and BMS-936559 (alone or in combination) resulted in complete response in 32% (19/60), and partial response in 38% (23/60) of malignant spindle cell melanoma patients, whose tumors contained a high percentage of CD274-positive cells (PMID: 29320474). | 29320474 |
| CD274 positive | malignant spindle cell melanoma | predicted - sensitive | Nivolumab | Clinical Study - Cohort | Actionable | In a retrospective analysis, PD-1 blockade therapies including Keytruda (pembrolizumab), Opdivo (nivolumab), and BMS-936559 (alone or in combination) resulted in complete response in 32% (19/60), and partial response in 38% (23/60) of malignant spindle cell melanoma patients, whose tumors contained a high percentage of CD274-positive cells (PMID: 29320474). | 29320474 | |
| CD274 positive | malignant spindle cell melanoma | predicted - sensitive | BMS-936559 | Clinical Study - Cohort | Actionable | In a retrospective analysis, PD-1 blockade therapies including Keytruda (pembrolizumab), Opdivo (nivolumab), and BMS-936559 (alone or in combination) resulted in complete response in 32% (19/60), and partial response in 38% (23/60) of malignant spindle cell melanoma patients, whose tumors contained a high percentage of CD274-positive cells (PMID: 29320474). | 29320474 | |
| CD274 positive | lung non-small cell carcinoma | sensitive | Pembrolizumab | Pembrolizumab | Guideline | Actionable | Keytruda (pembrolizumab) is included in guidelines as first-line and as continued maintenance therapy for patients with advanced or metastatic non-small cell lung cancer, not otherwise specified, with CD274 (PD-L1) expression of 1% to 49% (category 2B) (NCCN.org). | detail... |
| CD274 positive | esophagus squamous cell carcinoma | predicted - sensitive | Camrelizumab | Phase I | Actionable | In a Phase I trial, Camrelizumab (SHR-1210) treatment resulted improved objective response rate (46.7%, 7/15 vs 11.1%, 1/9, p>0.05) and disease control rate (66.7%, 10/15 vs 33.3%, 3/9) in patients with CD274 (PD-L1)-positive advanced esophageal squamous cell carcinoma compared to patients with CD274 (PD-L1)-negative tumors (PMID: 29358502; NCT02742935). | 29358502 | |
| CD274 positive | cervical cancer | sensitive | Pembrolizumab | Pembrolizumab | FDA approved - On Companion Diagnostic | Actionable | In a Phase II trial (KEYNOTE-158) that supported FDA approval, treatment with Keytruda (pembrolizumab) resulted in an objective response rate of 14.6% (12/82) in patients with CD274 (PD-L1)-positive (CPS >=1) advanced cervical cancer, including 3 with a complete response and 9 with a partial response (PMID: 30943124; NCT02628067). | 30943124 detail... detail... |
| CD274 positive | transitional cell carcinoma | sensitive | Atezolizumab | Atezolizumab | Phase II | Actionable | In a Phase II trial (IMvigor210), treatment with Tecentriq (atezolizumab) resulted in an objective response rate (ORR) of 23% (27/119) in cisplatin-ineligible patients with previously untreated, locally advanced or metastatic urothelial cancer, and ORR was 28% (9/32, 4 complete responses, 5 partial responses) in patients with immune cell CD274 (PD-L1) expression greater than or equal to 5% (PMID: 27939400; NCT02108652). | 27939400 |
| CD274 positive | transitional cell carcinoma | sensitive | Pembrolizumab | Pembrolizumab | Phase II | Actionable | In a Phase II (KEYNOTE-052) trial, Keytruda (pembrolizumab) treatment resulted in objective response in 24% (89/370) of cisplatin-ineligible patients with urothelial cancer, patients with an expression of CD274 (PD-L1) over 10% demonstrated improved response, with an objective response rate of 38% (42/110) (PMID: 28967485; NCT02335424). | 28967485 |
| CD274 positive | bladder urothelial carcinoma | sensitive | Pembrolizumab | Pembrolizumab | Phase II | Actionable | In a Phase II clinical study (PURE-01), neoadjuvant Keytruda (pembrolizumab) treatment in patients with muscle invasive bladder cancer with CD274 (PD-L1) combined positive scores greater than or equal to 10% resulted in a 54.3% (19/35) complete pathological response at resection compared to a 13.3% (2/15) complete pathological response at resection in patients with CD274 (PD-L1) CPS less than 10% (PMID: 30343614; NCT02736266). | 30343614 |
| CD274 positive | glioblastoma | no benefit | Nivolumab | Clinical Study - Cohort | Actionable | In a retrospective analysis, response to Keytruda (pembrolizumab) or Opdivo (nivolumab) therapy was not predicted by RNA expression levels of CD274 (PD-L1) in glioblastoma patients (PMID: 30742119). | 30742119 | |
| CD274 positive | glioblastoma | conflicting | Pembrolizumab | Pembrolizumab | Clinical Study - Cohort | Actionable | In a retrospective analysis, response to Keytruda (pembrolizumab) or Opdivo (nivolumab) therapy was not predicted by RNA expression levels of CD274 (PD-L1) in glioblastoma patients (PMID: 30742119). | 30742119 |
| CD274 positive | renal cell carcinoma | predicted - sensitive | Avelumab + Axitinib | Phase III | Actionable | In a Phase III trial (JAVELIN Renal 101), Inlyta (axitinib) plus Bavencio (avelumab) treatment resulted in a median progression-free survival of 13.8 mo. vs. 7.2 mo. with Sutent (sunitinib), and an objective response rate of 55.2% vs. 25.5% with Sutent (sunitinib) in patients with PD-L1-positive renal cell carcinoma, and at median follow-up 13.7% (37) of patients treated with Inlyta (axitinib) plus Bavencio (avelumab) had died vs. 15.2% (44) with Sutent (sunitinib) (PMID: 30779531; NCT02684006). | 30779531 | |
| CD274 positive | salivary gland carcinoma | predicted - sensitive | Pembrolizumab | Pembrolizumab | Phase I | Actionable | In a Phase Ib trial (KEYNOTE-028), Keytruda (pembrolizumab) treatment resulted in an objective response rate of 12% (3/26) and a stable disease rate of 46% (12/26) in heavily pretreated patients with salivary gland carcinoma that had CD274 (PD-L1) expression in 1% or more of tumor or stroma cells by IHC, with a median duration of response of 4 months (PMID: 29462123; NCT02054806). | detail... 29462123 |
| CD274 positive | malignant pleural mesothelioma | predicted - sensitive | Pembrolizumab | Pembrolizumab | Phase I | Actionable | In a Phase Ib trial (KEYNOTE-028), Keytruda (pembrolizumab) treatment demonstrated safety and preliminary efficacy, resulted in an objective response rate of 20% (5/25) and a stable disease rate of 52% (13/25) in previously treated patients with malignant pleural mesothelioma that had CD274 (PD-L1) expression in 1% or more of tumor cells by IHC, with a median duration of response of 12 months (PMID: 28291584; NCT02054806). | 28291584 |
| CD274 positive | neuroendocrine tumor | predicted - sensitive | Pembrolizumab | Pembrolizumab | Phase I | Actionable | In a Phase Ib trial (KEYNOTE-028), Keytruda (pembrolizumab) treatment demonstrated safety and preliminary efficacy, resulted in objective response in 12% (3/25) of heavily pretreated patients with carcinoid tumors (lung, n=9; gut, n=7; other, n=9) and in 6% (1/16) of patients with pancreatic neuroendocrine tumors that had CD274 (PD-L1) expression in 1% or more of tumor cells by IHC, with stable disease in 60% (15/25) and 88% (14/16) of the patients respectively (Ann Oncol, 28(Suppl_5); NCT02054806). | detail... |
| CD274 positive | anal canal squamous cell carcinoma | predicted - sensitive | Pembrolizumab | Pembrolizumab | Phase I | Actionable | In a Phase Ib trial (KEYNOTE-028), Keytruda (pembrolizumab) treatment demonstrated safety and preliminary efficacy, resulted in partial response in 17% (4/24) and stable disease in 42% (10/24) of patients with CD274 (PD-L1)-positive (1% or more) squamous cell carcinoma of the anal canal (PMID: 28453692; NCT02054806). | 28453692 |
| CD274 positive | endometrial cancer | predicted - sensitive | Pembrolizumab | Pembrolizumab | Phase I | Actionable | In a Phase Ib trial (KEYNOTE-028), Keytruda (pembrolizumab) treatment demonstrated safety and preliminary efficacy, resulted in partial response in 13% (3/24) and stable disease in 13% (3/24) of patients with heavily pretreated CD274 (PD-L1)-positive endometrial cancer (PMID: 28489510; NCT02054806). | 28489510 |
| CD274 positive | nasopharynx carcinoma | sensitive | Pembrolizumab | Pembrolizumab | Phase I | Actionable | In a Phase Ib trial (KEYNOTE-028), Keytruda (pembrolizumab) treatment demonstrated safety and preliminary efficacy, resulted in partial response in 25.9% (7/27) and stable disease in 51.9% (14/27) of patients with nasopharynx carcinoma that had CD274 (PD-L1) expression in 1% or more of tumor cells or tumor-infiltrating lymphocytes (PMID: 28837405; NCT02054806). | 28837405 |
| CD274 positive | colorectal carcinoma | predicted - sensitive | Pembrolizumab | Pembrolizumab | Phase I | Actionable | In a Phase Ib trial (KEYNOTE-028), Keytruda (pembrolizumab) treatment demonstrated safety and preliminary efficacy, resulted in partial response in 4% (1/24) and stable disease in 17% (4/24) of pretreated patients with CD274 (PD-L1)-positive colorectal carcinoma (PMID: 29284010; NCT02054806). | 29284010 |
| CD274 positive | prostate adenocarcinoma | predicted - sensitive | Pembrolizumab | Pembrolizumab | Phase I | Actionable | In a Phase Ib trial (KEYNOTE-028), Keytruda (pembrolizumab) treatment demonstrated safety and preliminary efficacy, resulted in partial response in 17.4% (4/23) and stable disease in 34.8% (8/23) of patients with CD274 (PD-L1)-positive (expression in 1% or more of tumor or stromal cells) advanced prostate adenocarcinoma (PMID: 29992241; NCT02054806). | 29992241 |
| CD274 positive | Her2-receptor negative breast cancer | predicted - sensitive | Pembrolizumab | Pembrolizumab | Phase I | Actionable | In a Phase Ib trial (KEYNOTE-028), Keytruda (pembrolizumab) treatment demonstrated safety and preliminary efficacy, resulted in partial response in 12% (3/25) and stable disease in 16% (4/25) of patients with CD274 (PD-L1)-positive (combined positive score >=1) advanced ER-positive, ERBB2 (HER2)-negative breast cancer, with a median duration of response of 12.0 months (PMID: 29559561; NCT02054806). | 29559561 |
| CD274 positive | thyroid gland carcinoma | predicted - sensitive | Pembrolizumab | Pembrolizumab | Phase I | Actionable | In a Phase Ib trial (KEYNOTE-028), Keytruda (pembrolizumab) treatment demonstrated safety and preliminary efficacy, resulted in partial response in 9% (2/22) of patients with CD274 (PD-L1)-positive (1% or more) papillary (n=15) or follicular (n=7) thyroid carcinoma, with a median progression-free survival of 7 months (PMID: 30832606; NCT02054806). | 30832606 |
| CD274 positive | lung small cell carcinoma | sensitive | Pembrolizumab | Pembrolizumab | Phase II | Actionable | In a Phase II trial (KEYNOTE-158), Keytruda (pembrolizumab) treatment resulted in superior objective response rate (35.7%, 15/24 vs 6.0%, 3/50), median progression-free survival (2.1 vs 1.9 months), and median overall survival (14.6 vs 7.7 months) in patients with CD274 (PD-L1)-positive (combined positive score>=1) advanced small cell lung cancer compared to patients with CD274 (PD-L1)-negative tumors (Journal of Clinical Oncology 36, no. 15_suppl (May 20 2018) 8506-8506; NCT02628067). | detail... |
| CD274 positive | triple-receptor negative breast cancer | sensitive | Atezolizumab + Nab-paclitaxel | Phase III | Actionable | In a Phase III trial (IMpassion130), Tecentriq (atezolizumab) in combination with Abraxane (nab-paclitaxel) resulted in improved progression-free survival (7.5 vs 5.0 months, HR=0.62, p<0.001) and overall survival (25.0 vs 15.5 months, HR=0.62) compared to placebo in patients with CD274 (PD-L1)-positive (>1%), advanced triple-receptor negative breast cancer (PMID: 30345906; NCT02425891). | detail... 30345906 detail... | |
| CD274 positive | lung non-squamous non-small cell carcinoma | sensitive | Nivolumab | Phase III | Actionable | In a Phase III trial (CheckMate 057), Opdivo (nivolumab) treatment demonstrated greater overall survival, progression-free survival, and objective response rate at all CD274 (PD-L1) expression levels analyzed (1% or more, 5% or more, 10% and more) in nonsquamous non-small cell lung carcinoma patients (PMID: 26412456; NCT01673867). | 26412456 | |
| CD274 positive | esophageal carcinoma | predicted - sensitive | Pembrolizumab | Pembrolizumab | Phase I | Actionable | In a Phase Ib trial (KEYNOTE-028), Keytruda (pembrolizumab) treatment resulted in an objective response rate of 30% (7/23, all partial responses), a median progression-free survival of 1.8 months, and a median overall survival of 7.0 months in patients with heavily pretreated, CD274 (PD-L1)-positive (1% or more) advanced esophageal carcinoma (PMID: 29116900; NCT02054806). | 29116900 |
| CD274 positive | pancreatic cancer | predicted - sensitive | CBP501 + Cisplatin + Nivolumab | Case Reports/Case Series | Actionable | In a Phase Ib trial, CBP501, Platinol (cisplatin), and Opdivo (nivolumab) triple combination therapy resulted in partial response in a patient with CD274 (PD-L1)-positive (70% tumor cells) pancreatic cancer (AACR Annual Meeting 2019, Abstract CT228; NCT03113188). | detail... | |
| CD274 positive | head and neck squamous cell carcinoma | sensitive | Pembrolizumab | Pembrolizumab | FDA approved - On Companion Diagnostic | Actionable | In a Phase III trial (KEYNOTE-048) that supported FDA approval, Keytruda (pembrolizumab) monotherapy significantly improved overall survival compared to Erbitux (cetuximab) plus chemotherapy (12.3 vs 10.3 months, HR=0.78, p=0.0086) in patients with CD274 (PD-L1)-positive (CPS >=1) metastatic or unresectable recurrent head and neck squamous cell carcinoma (PMID: 31679945; NCT02358031). | detail... 31679945 detail... |
| CD274 positive | Advanced Solid Tumor | predicted - sensitive | CDX-527 | Preclinical - Cell culture | Actionable | In a preclinical study, CDX-527 inhibited PD-1 signaling, and stimulated T cell response in culture (AACR Annual Meeting 2019, Abstract 2392). | detail... | |
| CD274 positive | melanoma | predicted - sensitive | Pembrolizumab | Pembrolizumab | Clinical Study - Cohort | Actionable | In a clinical study, PD-L1 (CD274) expression in primary melanomas, but not the PD-L1 status of advancing edges or metastases, was associated with higher 6-month objective response rate (35.7% in PD-L1 positive vs. 5% in PD-L1 negative; p=0.02) following treatment with Keytruda (pembrolizumab) or Opdivo (nivolumab) in patients with metastatic melanoma (PMID: 29973670). | 29973670 |
| CD274 positive | melanoma | predicted - sensitive | Nivolumab | Clinical Study - Cohort | Actionable | In a clinical study, PD-L1 (CD274) expression in primary melanomas, but not the PD-L1 status of advancing edges or metastases, was associated with higher 6-month objective response rate (35.7% in PD-L1 positive vs. 5% in PD-L1 negative; p=0.02) following treatment with Keytruda (pembrolizumab) or Opdivo (nivolumab) in patients with metastatic melanoma (PMID: 29973670). | 29973670 | |
| CD274 positive | bladder urothelial carcinoma | sensitive | Atezolizumab | Atezolizumab | Phase II | Actionable | In a Phase II trial (IMvigor210), treatment with Tecentriq (atezolizumab) resulted in an objective response rate (ORR) of 23% (27/119) in cisplatin-ineligible patients with previously untreated, locally advanced or metastatic urothelial cancer, and ORR was 28% (9/32, 4 complete responses, 5 partial responses) in patients with immune cell CD274 (PD-L1) expression greater than or equal to 5% (PMID: 27939400; NCT02108652). | 27939400 |
| CD274 positive | bladder urothelial carcinoma | sensitive | Pembrolizumab | Pembrolizumab | Phase II | Actionable | In a Phase II (KEYNOTE-052) trial, Keytruda (pembrolizumab) treatment resulted in objective response in 24% (89/370) of cisplatin-ineligible patients with urothelial cancer, patients with an expression of CD274 (PD-L1) over 10% demonstrated improved response, with an objective response rate of 38% (42/110) (PMID: 28967485; NCT02335424). | 28967485 |
| CD274 positive | cervical cancer | sensitive | Pembrolizumab | Pembrolizumab | Guideline | Actionable | Keytruda (pembrolizumab) is included in guidelines as second-line or subsequent therapy for patients with CD274 (PD-L1)-positive cervical cancer (NCCN.org). | detail... |
| CD274 positive | esophagus squamous cell carcinoma | sensitive | Pembrolizumab | Pembrolizumab | Guideline | Actionable | Keytruda (pembrolizumab) is included in guidelines as a preferred second-line or subsequent therapy (category 1) for patients with CD274 (PD-L1)-positive (CPS >/=10), unresectable locally advanced, recurrent, or metastatic esophageal squamous cell carcinoma (NCCN.org). | detail... |
| CD274 positive | stomach cancer | no benefit | Toripalimab-tpzi | Phase Ib/II | Actionable | In a Phase I/II trial, Loqtorz (toripalimab-tpzi) treatment resulted in an objective response rate (ORR) of 12.1% (7/58, 7 partial responses) and a disease control rate of 39.7% (23/58) in patients with advanced gastric cancer, the CD274 (PD-L1)-positive group demonstrated improved ORR (3/8, 37.5% vs 4/47, 8.5%, p=0.023) but not overall survival (12.1 vs 5.3 months, p=0.45) compared to the CD274 (PD-L1)-negative group (PMID: 31236579; NCT02915432). | 31236579 | |
| CD274 positive | Advanced Solid Tumor | predicted - sensitive | Toripalimab-tpzi | Phase I | Actionable | In a Phase I trial, patients with CD274 (PD-L1)-positive (membrane staining in 1% or more of tumor cells, n=16) advanced solid tumors demonstrated improved objective response rate (ORR) (43.8% vs 0%, p=0.0081) and progression-free survival (HR=0.36, p=0.034) compared to CD274 (PD-L1)-negative (n=12) patients in response to Loqtorz (toripalimab-tpzi) treatment, with an ORR of 57.1% in CD274 (PD-L1)-high (membrane staining in >50% of tumor cells, n=7) patients (PMID: 30642373; NCT02836795). | 30642373 | |
| CD274 positive | gastric adenocarcinoma | sensitive | Pembrolizumab | Pembrolizumab | Phase II | Actionable | In a Phase II trial (KEYNOTE-059) that supported FDA approval, Keytruda (pembrolizumab) treatment resulted in an objective response rate of 15.5% (23/148, complete response 3, partial response 20) with a median response duration of 16.3 months in patients with CD274 (PD-L1)-positive (CPS >1) gastric cancer or gastroesophageal junction adenocarcinoma (PMID: 29543932; NCT02335411). | 29543932 |
| CD274 positive | esophagus squamous cell carcinoma | sensitive | Pembrolizumab | Pembrolizumab | FDA approved - On Companion Diagnostic | Actionable | In a Phase III trial (KEYNOTE-181) that supported FDA approval, Keytruda (pembrolizumab) treatment as second-line therapy improved overall survival (OS) (9.3 vs 6.7 months, HR=0.69, p=0.0074) and 12-month OS rate (43% vs 20%) compared to chemotherapy in patients with esophagus squamous cell carcinoma with a CPS of 10 or higher (PMID: 33026938; NCT02564263). | detail... detail... 33026938 |
| CD274 positive | lung non-small cell carcinoma | sensitive | SL-279252 | Preclinical - Cell culture | Actionable | In a preclinical study, SL-279252 treatment coupled the activation of T-lymphocytes with induction of tumor cell apoptosis in a coculture of CD274-positive non-small cell lung cancer cells and CD3-positive T-lymphocytes (PMID: 30563566). | 30563566 | |
| CD274 positive | malignant peripheral nerve sheath tumor | predicted - sensitive | Pembrolizumab | Pembrolizumab | Case Reports/Case Series | Actionable | In a clinical case study, Keytruda (pembrolizumab) treatment resulted in complete metabolic response after 4 cycles of treatment in a patient with CD274 (PD-L1)-positive malignant peripheral nerve sheath tumor, and the patient stayed on treatment for 21 cycles (PMID: 31383651). | 31383651 |
| CD274 positive | lung non-small cell carcinoma | no benefit | Nivolumab | Phase III | Actionable | In a Phase III trial, treatment with Opdivo (nivolumab) did not result in longer median progression-free survival (PFS) or overall survival (OS) than chemotherapy treatment in patients with stage IV or recurrent non-small cell lung cancer with PD-L1 (CD274) expression of greater than 5%, resulting in a median PFS of 4.2 mo vs. 5.9 mo with chemotherapy (HR=1.15; 95% CI 0.91-1.45; p=0.25) and a median OS of 14.4 mo vs. 13.2 mo with chemotherapy (HR=1.15; 95% CI 0.80-1.30) (PMID: 28636851; NCT02041533). | 28636851 | |
| CD274 positive | bladder urothelial carcinoma | sensitive | Atezolizumab | Atezolizumab | Guideline | Actionable | Tecentriq (atezolizumab) is included in guidelines as a first-line therapy (category 2B) for cisplatin-ineligible bladder urothelial carcinoma patients with immune cell CD274 (PD-L1) expression greater than or equal to 5% (NCCN.org). | detail... |
| CD274 positive | lung adenocarcinoma | predicted - sensitive | Nab-paclitaxel + Pembrolizumab | Case Reports/Case Series | Actionable | In a clinical case study, a lung adenocarcinoma patient with CD274 (PD-L1) expression of 30% and harboring CD74-ROS1 and ROS1 G2032K demonstrated a partial response after being treated with the combination therapy of Keytruda (pembrolizumab) and Abraxane (nab-paclitaxel) for two cycles (PMID: 32208297). | 32208297 | |
| CD274 positive | Hodgkin's lymphoma | predicted - sensitive | Pembrolizumab | Pembrolizumab | Phase Ib/II | Actionable | In a Phase I/II trial (KEYNOTE-051), Keytruda (pembrolizumab) treatment resulted in an objective response rate of 60.0% (9/15, 2 complete response, 7 partial response) and a disease control rate of 80.0% in pediatric patients with CD274 (PD-L1)-positive Hodgkin's lymphoma, with a median progression-free survival of 12.2 months (PMID: 31812554; NCT02332668). | 31812554 |
| CD274 positive | Advanced Solid Tumor | predicted - sensitive | Pembrolizumab | Pembrolizumab | Phase Ib/II | Actionable | In a Phase I/II trial (KEYNOTE-051), Keytruda (pembrolizumab) treatment resulted in an objective response rate of 5.9% (8/136, 8 partial response) and a disease control rate of 26.5% in pediatric patients with CD274 (PD-L1)-positive advanced solid tumors, with a median progression-free survival of 1.9 months and a median overall survival of 9.0 months (PMID: 31812554; NCT02332668). | 31812554 |
| CD274 positive | adrenocortical carcinoma | predicted - sensitive | Pembrolizumab | Pembrolizumab | Case Reports/Case Series | Actionable | In a Phase I/II trial (KEYNOTE-051), Keytruda (pembrolizumab) treatment resulted in a partial response in 2 pediatric patients with CD274 (PD-L1)-positive adrenocortical carcinoma (PMID: 31812554; NCT02332668). | 31812554 |
| CD274 positive | malignant mesothelioma | predicted - sensitive | Pembrolizumab | Pembrolizumab | Case Reports/Case Series | Actionable | In a Phase I/II trial (KEYNOTE-051), Keytruda (pembrolizumab) treatment resulted in a partial response in 2 pediatric patients with CD274 (PD-L1)-positive mesothelioma (PMID: 31812554; NCT02332668). | 31812554 |
| CD274 positive | ganglioglioma | predicted - sensitive | Pembrolizumab | Pembrolizumab | Case Reports/Case Series | Actionable | In a Phase I/II trial (KEYNOTE-051), Keytruda (pembrolizumab) treatment resulted in a partial response in a pediatric patient with CD274 (PD-L1)-positive ganglioglioma (PMID: 31812554; NCT02332668). | 31812554 |
| CD274 positive | epithelioid sarcoma | predicted - sensitive | Pembrolizumab | Pembrolizumab | Case Reports/Case Series | Actionable | In a Phase I/II trial (KEYNOTE-051), Keytruda (pembrolizumab) treatment resulted in a partial response in a pediatric patient with CD274 (PD-L1)-positive epithelioid sarcoma (PMID: 31812554; NCT02332668). | 31812554 |
| CD274 positive | lymphoepithelioma-like carcinoma | predicted - sensitive | Pembrolizumab | Pembrolizumab | Case Reports/Case Series | Actionable | In a Phase I/II trial (KEYNOTE-051), Keytruda (pembrolizumab) treatment resulted in a partial response in a pediatric patient with CD274 (PD-L1)-positive lymphoepithelial carcinoma (PMID: 31812554; NCT02332668). | 31812554 |
| CD274 positive | rhabdoid cancer | predicted - sensitive | Pembrolizumab | Pembrolizumab | Case Reports/Case Series | Actionable | In a Phase I/II trial (KEYNOTE-051), Keytruda (pembrolizumab) treatment resulted in a partial response in a pediatric patient with CD274 (PD-L1)-positive rhabdoid cancer (PMID: 31812554; NCT02332668). | 31812554 |
| CD274 positive | high grade glioma | predicted - sensitive | Pembrolizumab | Pembrolizumab | Case Reports/Case Series | Actionable | In a Phase I/II trial (KEYNOTE-051), Keytruda (pembrolizumab) treatment resulted in size reduction of target lesion in 2 pediatric patients with CD274 (PD-L1)-positive high-grade glioma (PMID: 31812554; NCT02332668). | 31812554 |
| CD274 positive | embryonal rhabdomyosarcoma | predicted - sensitive | Pembrolizumab | Pembrolizumab | Case Reports/Case Series | Actionable | In a Phase I/II trial (KEYNOTE-051), Keytruda (pembrolizumab) treatment resulted in size reduction of target lesion in 2 pediatric patients with CD274 (PD-L1)-positive embryonal rhabdomyosarcoma (PMID: 31812554; NCT02332668). | 31812554 |
| CD274 positive | sarcoma | predicted - sensitive | Pembrolizumab | Pembrolizumab | Case Reports/Case Series | Actionable | In a Phase I/II trial (KEYNOTE-051), Keytruda (pembrolizumab) treatment resulted in size reduction of target lesion in 2 pediatric patients with CD274 (PD-L1)-positive soft tissue sarcoma (PMID: 31812554; NCT02332668). | 31812554 |
| CD274 positive | glioblastoma | conflicting | Pembrolizumab | Pembrolizumab | Case Reports/Case Series | Actionable | In a Phase I/II trial (KEYNOTE-051), Keytruda (pembrolizumab) treatment resulted in size reduction of target lesion in a pediatric patient with CD274 (PD-L1)-positive glioblastoma (PMID: 31812554; NCT02332668). | 31812554 |
| CD274 positive | chordoma | predicted - sensitive | Pembrolizumab | Pembrolizumab | Case Reports/Case Series | Actionable | In a Phase I/II trial (KEYNOTE-051), Keytruda (pembrolizumab) treatment resulted in size reduction of target lesion in a pediatric patient with CD274 (PD-L1)-positive chordoma (PMID: 31812554; NCT02332668). | 31812554 |
| CD274 positive | high grade ependymoma | predicted - sensitive | Pembrolizumab | Pembrolizumab | Case Reports/Case Series | Actionable | In a Phase I/II trial (KEYNOTE-051), Keytruda (pembrolizumab) treatment resulted in size reduction of target lesion in a pediatric patient with CD274 (PD-L1)-positive ependymoma (PMID: 31812554; NCT02332668). | 31812554 |
| CD274 positive | hepatoblastoma | predicted - sensitive | Pembrolizumab | Pembrolizumab | Case Reports/Case Series | Actionable | In a Phase I/II trial (KEYNOTE-051), Keytruda (pembrolizumab) treatment resulted in size reduction of target lesion in a pediatric patient with CD274 (PD-L1)-positive hepatoblastoma (PMID: 31812554; NCT02332668). | 31812554 |
| CD274 positive | neuroblastoma | predicted - sensitive | Pembrolizumab | Pembrolizumab | Case Reports/Case Series | Actionable | In a Phase I/II trial (KEYNOTE-051), Keytruda (pembrolizumab) treatment resulted in size reduction of target lesion in a pediatric patient with CD274 (PD-L1)-positive neuroblastoma (PMID: 31812554; NCT02332668). | 31812554 |
| CD274 positive | ganglioneuroblastoma | predicted - sensitive | Pembrolizumab | Pembrolizumab | Case Reports/Case Series | Actionable | In a Phase I/II trial (KEYNOTE-051), Keytruda (pembrolizumab) treatment resulted in size reduction of target lesion in a pediatric patient with CD274 (PD-L1)-positive ganglioneuroblastoma (PMID: 31812554; NCT02332668). | 31812554 |
| CD274 positive | congenital mesoblastic nephroma | predicted - sensitive | Pembrolizumab | Pembrolizumab | Case Reports/Case Series | Actionable | In a Phase I/II trial (KEYNOTE-051), Keytruda (pembrolizumab) treatment resulted in size reduction of target lesion in a pediatric patient with CD274 (PD-L1)-positive mesoblastic nephroma (PMID: 31812554; NCT02332668). | 31812554 |
| CD274 positive | fibrosarcoma of bone | predicted - sensitive | Pembrolizumab | Pembrolizumab | Case Reports/Case Series | Actionable | In a Phase I/II trial (KEYNOTE-051), Keytruda (pembrolizumab) treatment resulted in size reduction of target lesion in a pediatric patient with CD274 (PD-L1)-positive malignant histiocytosis (PMID: 31812554; NCT02332668). | 31812554 |
| CD274 positive | inflammatory myofibroblastic tumor | predicted - sensitive | Pembrolizumab | Pembrolizumab | Case Reports/Case Series | Actionable | In a Phase I/II trial (KEYNOTE-051), Keytruda (pembrolizumab) treatment resulted in size reduction of target lesion in a pediatric patient with CD274 (PD-L1)-positive inflammatory myofibroblastic tumor (PMID: 31812554; NCT02332668). | 31812554 |
| CD274 positive | lung cancer | predicted - sensitive | MCLA-145 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, MCLA-145 treatment inhibited tumor growth in a cell line xenograft model of CD274 (PD-L1) and NY-ESO-positive lung cancer that had adoptive transfer of human T-cells expressing NY-ESO specific T-cell receptors (Cancer Res 2019;79(13 Suppl):Abstract nr 539). | detail... | |
| CD274 positive | ovarian cancer | predicted - sensitive | Atezolizumab + Magrolimab | Case Reports/Case Series | Actionable | In a Phase Ib trial, Tecentriq (atezolizumab) and Magrolimab (Hu5F9-G4) combination therapy resulted in tumor shrinkage in a patient with platinum-resistant ovarian cancer with tumor CD274 (PD-L1) expression (J Clin Oncol 38, 2020 (suppl 5; abstr 18); NCT03558139). | detail... | |
| CD274 positive | lung non-small cell carcinoma | predicted - sensitive | Atezolizumab + Tiragolumab | Phase II | Actionable | In a Phase II trial (CITYSCAPE), Tiragolumab (MTIG7192A) and Tecentriq (atezolizumab) combination therapy as first-line treatment improved objective response rate (37.3%, 25/67 vs 20.6%, 14/68) and median progression-free survival (5.6 vs 3.9 mo) compared to Tecentriq (atezolizumab) plus placebo in patients with CD274 (PD-L1)-positive (TPS>=1%) advanced or metastatic non-small cell lung cancer (J Clin Oncol 38, no. 15_suppl (May 20, 2020) 9503-9503; NCT03563716). | detail... | |
| CD274 positive | transitional cell carcinoma | sensitive | Avelumab | Phase III | Actionable | In a Phase III trial (JAVELIN Bladder 100), addition of maintenance Bavencio (avelumab) to best supportive care (BSC) significantly improved overall survival compared to BSC alone (not reached vs 17.1 mo, HR=0.56, p=0.0003) in patients with CD274 (PD-L1)-positive advanced urothelial carcinoma (J Clin Oncol 38, (Jun 2020) no. 18_suppl; NCT02603432). | detail... | |
| CD274 positive | Her2-receptor positive breast cancer | not predictive | Ado-trastuzumab emtansine | Phase III | Actionable | In a retrospective analysis of a Phase III trial (KATHERINE), CD274 (PD-L1) expression was not associated with invasive disease-free survival (HR=1.05) in patients with Erbb2 (Her2)-positive breast cancer treated with adjuvant Kadcyla (ado-trastuzumab emtansine), who had residual invasive disease after neoadjuvant therapy (PMID: 36730339; NCT01772472). | 36730339 | |
| CD274 positive | Her2-receptor positive breast cancer | predicted - sensitive | Trastuzumab | Phase III | Actionable | In a retrospective analysis of a Phase III trial (KATHERINE), CD274 (PD-L1) expression was associated with invasive disease-free survival (HR=0.66) in patients with Erbb2 (Her2)-positive breast cancer treated with adjuvant Herceptin (trastuzumab), who had residual invasive disease after neoadjuvant therapy (PMID: 36730339; NCT01772472). | 36730339 | |
| CD274 positive | lung adenocarcinoma | sensitive | Pembrolizumab | Pembrolizumab | Guideline | Actionable | Keytruda (pembrolizumab) is included in guidelines as first-line and as continued maintenance therapy for patients with advanced or metastatic lung adenocarcinoma with CD274 (PD-L1) expression of 1% to 49%, and negative for actionable molecular biomarkers (category 2B) (NCCN.org). | detail... |
| CD274 positive | lung large cell carcinoma | sensitive | Pembrolizumab | Pembrolizumab | Guideline | Actionable | Keytruda (pembrolizumab) is included in guidelines as first-line and as continued maintenance therapy for patients with advanced or metastatic lung large cell carcinoma with CD274 (PD-L1) expression of 1% to 49%, and negative for actionable molecular biomarkers (category 2B) (NCCN.org). | detail... |
| CD274 positive | lung squamous cell carcinoma | sensitive | Pembrolizumab | Pembrolizumab | Guideline | Actionable | Keytruda (pembrolizumab) is included in guidelines as first-line and as continued maintenance therapy for patients with advanced or metastatic lung squamous cell carcinoma with CD274 (PD-L1) expression of 1% to 49%, and negative for actionable molecular biomarkers (category 2B) (NCCN.org). | detail... |
| CD274 positive | melanoma | predicted - sensitive | Toripalimab-tpzi | Phase II | Actionable | In a Phase II trial (POLARIS-01), Loqtorz (toripalimab-tpzi) resulted in a more favorable objective response rate (38.5% vs 11.9%, p=0.0065), disease control rate (80.8% vs 48.8%, p=0.006), progression-free survival (7.7 vs 2.7 mo, HR=0.53, p=0.013), and overall survival (not reached vs 14.4 mo, HR=0.35, p=0.0005) in patients with CD274 (PD-L1)-positive advanced melanoma (n=26) compared to patients with CD274 (PD-L1)-negative (n=84) tumors (PMID: 32321714; NCT03013101). | 32321714 | |
| CD274 positive | anal canal cancer | predicted - sensitive | Spartalizumab | Case Reports/Case Series | Actionable | In a Phase I trial, Spartalizumab (PDR001) treatment in a patient with CD274 (PD-L1)-positive anal cancer resulted in a partial response lasting 1.8 months, with a combined 31% reduction of target lesion size (PMID: 32179633; NCT02404441). | 32179633 | |
| CD274 positive | anaplastic thyroid carcinoma | predicted - sensitive | Spartalizumab | Phase II | Actionable | In a Phase II trial, Spartalizumab (PDR001) was tolerated in patients with anaplastic thyroid carcinoma, and resulted in an overall response rate (ORR) of 19% (8/42, 3 complete responses, 5 partial responses), median progression-free survival of 1.7 mo, and median overall survival of 5.9 mo; ORR was higher in patients with tumor PD-L1 >=1% compared to PD-L1<1% (29%, 8/28 vs 0%, 0/12, p=0.079), and highest ORR (35%) was observed in patients with PD-L1 >= 50% (PMID: 32364844; NCT02404441). | 32364844 | |
| CD274 positive | lung non-small cell carcinoma | predicted - sensitive | Nivolumab + Pegilodecakin | Phase I | Actionable | In a Phase Ib trial (IVY), Pegilodecakin (AM0010) and Keytruda (pembrolizumab) (n=5) or Opdivo (nivolumab) (n=29) combination therapy demonstrated safety and preliminary efficacy in patients with non-small cell lung carcinoma, objective response was observed in 83% (5/6) of patients with CD274 (PD-L1) expression of 50% or higher, and in 67% (2/3) of patients with CD274 (PD-L1) expression less than 50% (PMID: 31563517; NCT02009449). | 31563517 | |
| CD274 positive | transitional cell carcinoma | predicted - sensitive | Nivolumab | Phase II | Actionable | In a Phase II trial (CheckMate 275), Opdivo (nivolumab) treatment in platinum-resistant urothelial carcinoma patients resulted in an objective response rate (ORR) of 20.7% (56/270), a median progression-free survival (mPFS) of 1.9 mo., and a median overall survival (mOS) of 8.6 mo., and patients with CD274 (PD-L1)-positive tumors (IHC>=1% compared to <1%) had improved ORR (25.8%, 32/124 v 16.4%, 24/146), mPFS (3.5 v 1.9 mo), and mOS (11.9 v 6.0 mo) (PMID: 32532789; NCT02387996). | 32532789 | |
| CD274 positive | triple-receptor negative breast cancer | sensitive | Pembrolizumab | Pembrolizumab | FDA approved - On Companion Diagnostic | Actionable | In a Phase III trial (KEYNOTE-355) that supported FDA approval, addition of Keytruda (pembrolizumab) to chemotherapy significantly improved progression-free survival compared to chemotherapy alone (9.7 vs 5.6, HR=0.65, p=0.0012) in patients with locally recurrent or metastatic triple-receptor negative breast cancer expressing CD274 (PD-L1, CPS>=10), as determined by an FDA-approved test (Journal of Clinical Oncology 38, no. 15_suppl (May 20, 2020) 1000-1000; NCT02819518). | detail... detail... detail... |
| CD274 positive | alveolar soft part sarcoma | not predictive | GB226 | Phase II | Actionable | In a Phase II trial (Gxplore-005), patients with CD274 (PD-L1)-positive (CPS >=1%) alveolar soft part sarcoma achieved an objective response rate (ORR) of 33.3% (4/12; 95% CI 9.9-65.1) and a disease control rate (DCR) of 83.3% (10/12; 95% CI 51.6-97.9) in response to Geptanolimab (GB226) treatment, which were not different from the 40.0% ORR (10/25; 95% CI 21.1-61.3) and 88.0% DCR (22/25; 95% CI 68.8-97.5) observed in CD274 (PD-L1)-negative (CPS <1%) patients (PMID: 33046518; NCT03623581). | 33046518 | |
| CD274 positive | hepatocellular carcinoma | not predictive | Camrelizumab + Rivoceranib | Clinical Study - Cohort | Actionable | In a Phase II trial (RESCUE), combined Camrelizumab (SHR-1210) and Rivoceranib (apatinib) treatment in patients with CD274 (PD-L1)-positive (TPS>=1%) advanced hepatocellular carcinoma demonstrated a similar objective response rate (31.8%, 7/22 vs. 18.8%, 6/32) and progression-free survival event rate (63.6%,14/22 vs. 75.0%, 24/32) compared to patients with CD274 (PD-L1)-negative (TPS<1%) tumors (PMID: 33087333; NCT03463876). | 33087333 | |
| CD274 positive | nasopharynx carcinoma | sensitive | Pembrolizumab | Pembrolizumab | Guideline | Actionable | Keytruda (pembrolizumab) is included in guidelines as a subsequent-line therapy (category 2B) for patients with CD274 (PD-L1)-positive, recurrent or metastatic nasopharynx cancer (NCCN.org). | detail... |
| CD274 positive | lung non-squamous non-small cell carcinoma | not predictive | Camrelizumab + Rivoceranib | Phase Ib/II | Actionable | In a Phase Ib/II trial, combined Camrelizumab (SHR-1210) and Rivoceranib (apatinib) treatment in patients with CD274 (PD-L1)-positive (TPS>=1%; n=25) non-squamous non-small cell lung cancer resulted in a similar objective response rate (36.0%, 9/25 vs 22.7%, 15/66; p=0.20), disease control rate (72.0%,18/25 vs 71.2%, 47/66; p=0.94), and median progression-free survival (6.8 vs 5.1 months; p=0.29) to patients with CD274 (PD-L1)-negative (TPS<1%; n=66) tumors (PMID: 33323401; NCT03083041). | 33323401 | |
| CD274 positive | lung adenocarcinoma | sensitive | Pembrolizumab | Pembrolizumab | Case Reports/Case Series | Actionable | In a clinical case study, a patient with CD274 (PD-L1)-positive (70% tumor cells) metastatic lung adenocarcinoma treated with Keytruda (pembrolizumab) achieved a complete response in multiple brain metastases prior to disease progression in a primary lung lesion after 9 months of treatment, but was subsequently treated with Tepmetko (tepotinib) due to the presence of a MET exon 14 skipping mutation, which resulted in prolonged disease stabilization with no recurrence of brain lesions (PMID: 33335011). | 33335011 |
| CD274 positive | diffuse large B-cell lymphoma | predicted - sensitive | CD19-PD-1/CD28-CAR T cells | Case Reports/Case Series | Actionable | In a Phase Ib trial, CD19-PD-1/CD28-CAR T cell treatment in two patients with CD274 positive diffuse large B-cell lymphoma resulted in complete remission (CR) after 3 months, however, disease progression was observed in one patient after 2 months, while the other patient achieved persistent CR. (PMID: 33028589). | 33028589 | |
| CD274 positive | lung adenocarcinoma | no benefit | LMB-100 | Preclinical - Cell culture | Actionable | In a preclinical study, a CD274 (PD-L1) positive mouse lung adenocarcinoma cell line was not sensitive to treatment with LMB-100 in culture (PMID: 32611684). | 32611684 | |
| CD274 positive | malignant mesothelioma | predicted - sensitive | Pembrolizumab | Pembrolizumab | Clinical Study | Actionable | In a clinical study, 80% (4/5) of MSLN positive mesothelioma patients with CD274 (PD-L1) expression who had progressed on LMB-100 demonstrated an objective response when treated with Keytruda (pembrolizumab), and compared to patients without CD274 expression (n=5), treatment significantly prolonged median progression-free survival (11.3 vs 2.1 mos, p<0.0018) but not overall survival (27.2 vs 6.8 mos, p=0.1) (PMID: 32611684). | 32611684 |
| CD274 positive | triple-receptor negative breast cancer | sensitive | Nab-paclitaxel + Pembrolizumab | Guideline | Actionable | Combination of Keytruda (pembrolizumab) and Abraxane (nab-paclitaxel) is included in guidelines as preferred first-line therapy for patients with recurrent unresectable or stage IV (M1) CD274 (PD-L1)-positive (CPS >/= 10) triple-receptor negative breast cancer (category 1) (NCCN.org). | detail... | |
| CD274 positive | triple-receptor negative breast cancer | sensitive | Paclitaxel + Pembrolizumab | Guideline | Actionable | Combination of Keytruda (pembrolizumab) and Taxol (paclitaxel) is included in guidelines as preferred first-line therapy for patients with recurrent unresectable or stage IV (M1) CD274 (PD-L1)-positive (CPS >/= 10) triple-receptor negative breast cancer (category 1) (NCCN.org). | detail... | |
| CD274 positive | triple-receptor negative breast cancer | sensitive | Carboplatin + Gemcitabine + Pembrolizumab | Guideline | Actionable | Combination of Keytruda (pembrolizumab), Paraplatin (carboplatin), and Gemzar (gemcitabine) is included in guidelines as preferred first-line therapy for patients with recurrent unresectable or stage IV (M1) CD274 (PD-L1)-positive (CPS >/= 10) triple-receptor negative breast cancer (category 1) (NCCN.org). | detail... | |
| CD274 positive | esophagus squamous cell carcinoma | sensitive | Cisplatin + Fluorouracil + Pembrolizumab | Phase III | Actionable | In a Phase III trial (KEYNOTE-590), addition of Keytruda (pembrolizumab) to cisplatin and fluorouracil significantly improved overall survival (13.9 vs 8.8 mo, HR=0.57, p<0.0001) and progression-free survival (6.3 vs 5.8 mo, HR=0.65, p<0.0001) in patients with metastatic or locally advanced esophageal squamous cell carcinoma expressing PD-L1 (CPS>=10) (Ann Oncol. 31, no. 4_suppl (Sep 2020) S1192-S1193; NCT03189719). | detail... | |
| CD274 positive | esophageal carcinoma | sensitive | Cisplatin + Fluorouracil + Pembrolizumab | Phase III | Actionable | In a Phase III trial (KEYNOTE-590), addition of Keytruda (pembrolizumab) to cisplatin and fluorouracil significantly improved overall survival (13.5 vs 9.4 mo, HR=0.62, p<0.0001) and progression-free survival (7.5 vs 5.5 mo, HR=0.51, p<0.0001) in patients with metastatic or locally advanced esophageal or gastroesophageal junction carcinoma expressing PD-L1 (CPS>=10) (Ann Oncol. 31, no. 4_suppl (Sep 2020) S1192-S1193; NCT03189719). | detail... | |
| CD274 positive | gastroesophageal junction adenocarcinoma | sensitive | Cisplatin + Fluorouracil + Pembrolizumab | Phase III | Actionable | In a Phase III trial (KEYNOTE-590), addition of Keytruda (pembrolizumab) to cisplatin and fluorouracil significantly improved overall survival (13.5 vs 9.4 mo, HR=0.62, p<0.0001) and progression-free survival (7.5 vs 5.5 mo, HR=0.51, p<0.0001) in patients with metastatic or locally advanced esophageal or gastroesophageal junction carcinoma expressing PD-L1 (CPS>=10) (Ann Oncol. 31, no. 4_suppl (Sep 2020) S1192-S1193; NCT03189719). | detail... | |
| CD274 positive | lung non-small cell carcinoma | predicted - sensitive | Durvalumab | Phase II | Actionable | In a Phase II trial (ATLANTIC), Imfinzi (durvalumab) treatment resulted in superior objective response rate in non-small cell lung cancer patients with 25% or more tumor cells expressing CD274 (PD-L1) compared to patients with CD274 (PD-L1) expression in less than 25% of tumor cells, in both the cohort harboring EGFR and ALK mutations (12.2% vs 3.6%) and the EGFR and ALK wild-type cohort (16.4% vs 7.5%) (PMID: 29545095; NCT02087423). | 29545095 | |
| CD274 positive | esophagus squamous cell carcinoma | sensitive | Tislelizumab | Clinical Study - Cohort | Actionable | In a Phase III trial (RATIONALE-302), second-line Tevimbra (tislelizumab) improved median overall survival (mOS) (8.6 vs 6.3 mo; HR 0.70, p=0.0001) and objective response rate (20.3% vs 9.8%) compared to chemotherapy in advanced esophageal squamous cell carcinoma patients, and CD274 (PD-L1)-positive (TAP>=10%) patients treated with Tevimbra (tislelizumab) (n=89) showed improved mOS (10.3 vs 6.8 mo; HR 0.54, p=0.0006) compared to those patients treated with chemotherapy (n=68) (PMID: 35442766; NCT03430843). | 35442766 | |
| CD274 positive | transitional cell carcinoma | predicted - sensitive | Retifanlimab | Phase II | Actionable | In a Phase II trial (POD1UM-203), Zynyz (retifanlimab) treatment was well tolerated and demonstrated antitumor activity in patients with CD274 (PD-L1)-positive (CPS >/= 10%) urothelial carcinoma, resulting in an overall response rate of 37.9% (11/29, 1 complete and 10 partial responses), disease control rate of 55.2%, median progression-free survival of 5.7 months, median duration or response of 11.5 months, and median overall survival of 15.2 months (PMID: 38401247; NCT03679767). | 38401247 | |
| CD274 positive | gastroesophageal junction adenocarcinoma | unknown | HX008 + Irinotecan | Phase II | Actionable | In a Phase II trial, CD274 (PD-L1)-positive gastric or gastroesophageal junction cancer patients treated with HX008 and Camptosar (irinotecan) achieved an objective response rate (ORR) of 38.5% (5/13), disease control rate (DCR) of 84.6% (11/13), median progression-free survival (mPFS) of 4.3 mo, and median overall survival (mOS) was not reached, compared to CD274 (PD-L1) negative patients with an ORR of 37.5% (3/8), DCR of 75% (6/8), mPFS of 5.0 mo, and mOS of 8.7 mo (PMID: 33060149; NCT03704246). | 33060149 | |
| CD274 positive | stomach cancer | unknown | HX008 + Irinotecan | Phase II | Actionable | In a Phase II trial, CD274 (PD-L1)-positive gastric or gastroesophageal junction cancer patients treated with HX008 and Camptosar (irinotecan) achieved an objective response rate (ORR) of 38.5% (5/13), disease control rate (DCR) of 84.6% (11/13), median progression-free survival (mPFS) of 4.3 mo, and median overall survival (mOS) was not reached, compared to CD274 (PD-L1) negative patients with an ORR of 37.5% (3/8), DCR of 75% (6/8), mPFS of 5.0 mo, and mOS of 8.7 mo (PMID: 33060149; NCT03704246). | 33060149 | |
| CD274 positive | rectum cancer | predicted - sensitive | OH2 | Case Reports/Case Series | Actionable | In a Phase I/II trial, a patient with CD274 (PD-L1)-positive (TPS=3) metastatic rectal cancer treated with OH2 in a liver metastasis achieved a partial response with reduced size of the injected and non-injected liver lesions 6.89 months after treatment initiation and discontinued treatment but maintained an ongoing response lasting over 11.25 months (PMID: 33837053). | 33837053 | |
| CD274 positive | esophageal cancer | predicted - sensitive | OH2 | Case Reports/Case Series | Actionable | In a Phase I/II trial, OH2 treatment in a CD274 (PD-L1)-positive (TPS=3) metastatic esophageal cancer patient led to an immune partial response 5.44 months after treatment initiation, followed by discontinuation of treatment, and an ongoing response lasting over 14.03 months (PMID: 33837053). | 33837053 | |
| CD274 positive | stomach cancer | not predictive | Capecitabine + HX008 + Oxaliplatin | Phase I | Actionable | In a Phase Ib trial, treatment with HX008, Xeloda (capecitabine), and Eloxatin (oxaliplatin) combination therapy resulted in an objective response rate (ORR) of 75% (9/12) and disease control rate (DCR) of 83.3% (10/12) in CD274 (PD-L1)-positive gastric or gastroesophageal junction cancer patients, compared to an ORR and DCR of 66.7% (6/9) and 100% (9/9) respectively in CD274 (PD-L1)-negative patients; however, no difference was observed in progression-free survival (p=0.19) (PMID: 33457083). | 33457083 | |
| CD274 positive | gastroesophageal junction adenocarcinoma | not predictive | Capecitabine + HX008 + Oxaliplatin | Phase I | Actionable | In a Phase Ib trial, treatment with HX008, Xeloda (capecitabine), and Eloxatin (oxaliplatin) combination therapy resulted in an objective response rate (ORR) of 75% (9/12) and disease control rate (DCR) of 83.3% (10/12) in CD274 (PD-L1)-positive gastric or gastroesophageal junction cancer patients, compared to an ORR and DCR of 66.7% (6/9) and 100% (9/9) respectively in CD274 (PD-L1)-negative patients; however, no difference was observed in progression-free survival (p=0.19) (PMID: 33457083). | 33457083 | |
| CD274 positive | triple-receptor negative breast cancer | predicted - sensitive | Eribulin + Pembrolizumab | Phase Ib/II | Actionable | In a Phase I/II trial, Keytruda (pembrolizumab) and Eribulin combination therapy demonstrated safety and clinical activity in patients with metastatic triple-negative breast cancer, patients with CD274 (PD-L1)-positive tumors achieved better objective response rate (28.4% vs 17.3%), median progression-free survival (4.2 vs 3.9 months), and overall survival (16.3 vs 15.2 months) compared to patients with CD274 (PD-L1)-negative tumors (PMID: 33727258; NCT02513472). | 33727258 | |
| CD274 positive | stomach cancer | sensitive | Nivolumab | Guideline | Actionable | Opdivo (nivolumab), in combination with first-line chemotherapy including fluoropyrimidine and oxaliplatin, is included in guidelines as preferred first-line therapy for patients with gastric cancer expressing PD-L1 (CD274, CPS>=5), and without ERBB2 (HER2) overexpression (category 1), and as first-line therapy for patients with PD-L1 expression (CD274, CPS <5) and without ERBB2 (HER2) overexpression (category 2B) (NCCN.org). | detail... | |
| CD274 positive | lung non-small cell carcinoma | sensitive | Ipilimumab + Nivolumab | Ipilimumab + Nivolumab | Guideline | Actionable | Combination Opdivo (nivolumab) plus Yervoy (ipilimumab) is in guidelines as first-line therapy (category 1) for advanced or metastatic non-small cell lung cancer patients with CD274 (PD-L1) expression >1% and negative for actionable molecular biomarkers (NCCN.org). | detail... |
| CD274 positive | transitional cell carcinoma | predicted - sensitive | Nivolumab | Phase III | Actionable | In a Phase III trial (CheckMate-274), adjuvant Opdivo (nivolumab) treatment significantly improved the percentage of patients who were alive and disease-free at 6 months (74.5% vs 55.7%, HR 0.55, P<0.001) and median recurrence-free survival (22.9 vs 13.7 mo) compared to placebo in patients with high-risk urothelial carcinoma with a PD-L1 expression level of 1% or more (PMID: 34077643; NCT02632409). | 34077643 | |
| CD274 positive | gastroesophageal junction adenocarcinoma | sensitive | Capecitabine + Oxaliplatin + Pembrolizumab | Guideline | Actionable | Keytruda (pembrolizumab) in combination with first-line chemotherapy including Xeloda (capecitabine) and Eloxatin (oxaliplatin) is included in guidelines as preferred first-line therapy for patients with locally advanced, recurrent, or metastatic ERBB2 (HER2) overexpression negative gastroesophageal junction adenocarcinoma expressing PD-L1 (CD274) with CPS >/= 1 (category 1) (NCCN.org). | detail... | |
| CD274 positive | gastroesophageal junction adenocarcinoma | sensitive | Cisplatin + Fluorouracil + Pembrolizumab | Guideline | Actionable | Keytruda (pembrolizumab) in combination with first-line chemotherapy including Adrucil (fluorouracil) and Platinol (cisplatin) is included in guidelines as preferred first-line therapy for patients with locally advanced, recurrent, or metastatic ERBB2 (HER2) overexpression negative gastroesophageal junction adenocarcinoma expressing PD-L1 (CD274) with CPS >/= 10 (category 1) or with CPS >/=1 and <10 (category 2B) (NCCN.org). | detail... | |
| CD274 positive | gastroesophageal junction adenocarcinoma | sensitive | Capecitabine + Cisplatin + Pembrolizumab | Guideline | Actionable | Keytruda (pembrolizumab) in combination with first-line chemotherapy including Xeloda (capecitabine) and Platinol (cisplatin) is included in guidelines as preferred first-line therapy for patients with locally advanced, recurrent, or metastatic ERBB2 (HER2) overexpression negative gastroesophageal junction adenocarcinoma expressing PD-L1 (CD274) with CPS >/= 10 (category 1) or with CPS >/=1 and <10 (category 2B) (NCCN.org). | detail... | |
| CD274 positive | lung non-small cell carcinoma | predicted - sensitive | Anlotinib + Cadonilimab | Phase Ib/II | Actionable | In a Phase Ib/II trial, combination treatment with Cadonilimab and Anlotinib (AL-3818) demonstrated antitumor activity in patients with CD274 (PD-L1) positive (TPS >= 1%) non-small cell lung cancer, and led to an objective response rate of 62.5% (5/8) and a disease control rate of 100% (8/8). (Annals of Oncology 32 (2021): S1006; NCT04646330). | detail... | |
| CD274 positive | cervical cancer | sensitive | Cisplatin + Paclitaxel + Pembrolizumab | FDA approved - On Companion Diagnostic | Actionable | In a Phase III trial (KEYNOTE-826) that supported FDA approval, first-line Keytruda (pembrolizumab) in combination with platinum-based chemotherapy (Platinol (cisplatin) or Paraplatin (carboplatin) plus Taxol (paclitaxel)), with or without Avastin (bevacizumab), improved progression-free survival (10.4 vs 8.1 mo, HR 0.62, p<0.001) compared to placebo in patients with CD274 (PD-L1)-positive (CPS>=1), persistent, recurrent or metastatic cervical cancer (PMID: 34534429; NCT03635567). | 34534429 detail... detail... | |
| CD274 positive | cervical cancer | sensitive | Bevacizumab + Cisplatin + Paclitaxel + Pembrolizumab | FDA approved - On Companion Diagnostic | Actionable | In a Phase III trial (KEYNOTE-826) that supported FDA approval, first-line Keytruda (pembrolizumab) in combination with platinum-based chemotherapy (Platinol (cisplatin) or Paraplatin (carboplatin) plus Taxol (paclitaxel)), with or without Avastin (bevacizumab), improved progression-free survival (10.4 vs 8.1 mo, HR 0.62, p<0.001) compared to placebo in patients with CD274 (PD-L1)-positive (CPS>=1), persistent, recurrent or metastatic cervical cancer (PMID: 34534429; NCT03635567). | 34534429 detail... detail... | |
| CD274 positive | cervical cancer | sensitive | Bevacizumab + Carboplatin + Paclitaxel + Pembrolizumab | FDA approved - On Companion Diagnostic | Actionable | In a Phase III trial (KEYNOTE-826) that supported FDA approval, first-line Keytruda (pembrolizumab) in combination with platinum-based chemotherapy (Platinol (cisplatin) or Paraplatin (carboplatin) plus Taxol (paclitaxel)), with or without Avastin (bevacizumab), improved progression-free survival (10.4 vs 8.1 mo, HR 0.62, p<0.001) compared to placebo in patients with CD274 (PD-L1)-positive (CPS>=1), persistent, recurrent or metastatic cervical cancer (PMID: 34534429; NCT03635567). | detail... detail... 34534429 | |
| CD274 positive | cervical cancer | sensitive | Carboplatin + Paclitaxel + Pembrolizumab | FDA approved - On Companion Diagnostic | Actionable | In a Phase III trial (KEYNOTE-826) that supported FDA approval, first-line Keytruda (pembrolizumab) in combination with platinum-based chemotherapy (Platinol (cisplatin) or Paraplatin (carboplatin) plus Taxol (paclitaxel)), with or without Avastin (bevacizumab), improved progression-free survival (10.4 vs 8.1 mo, HR 0.62, p<0.001) compared to placebo in patients with CD274 (PD-L1)-positive (CPS>=1), persistent, recurrent or metastatic cervical cancer (PMID: 34534429; NCT03635567). | detail... 34534429 detail... | |
| CD274 positive | lung non-small cell carcinoma | sensitive | Atezolizumab | Atezolizumab | FDA approved - On Companion Diagnostic | Actionable | In a Phase III trial (IMpower010) that supported FDA approval, adjuvant Tecentriq (atezolizumab) treatment following resection and chemotherapy improved disease-free survival compared to best supportive care (HR 0·66, p=0·0039) in patients with stage II-IIIA non-small cell lung cancer whose tumors expressed CD274 (PD-L1) on 1% or more of tumor cells (PMID: 34555333; NCT02486718). | detail... 34555333 detail... |
| CD274 positive | lung non-small cell carcinoma | predicted - sensitive | Durvalumab + Vactosertib | Phase Ib/II | Actionable | In a Phase Ia/II trial, combination treatment with Vactosertib (TEW 7197) and Imfinzi (durvalumab) demonstrated safety and antitumor activity in CD274 (PD-L1)-positive non-small cell lung cancer patients, and led to an objective response rate of 30.8% and 40.0% in patients with CD274 (PD-L1) expression >= 1% and >=25% respectively (Journal for ImmunoTherapy of Cancer 2020;8; NCT03732274). | detail... | |
| CD274 positive | lung non-small cell carcinoma | sensitive | Atezolizumab | Atezolizumab | Guideline | Actionable | Tecentriq (atezolizumab) is included in guidelines as adjuvant therapy (category 1) for non-small cell lung cancer patients with PD-L1 expression >/= 1% and negative for EGFR exon 19 deletion, L858R, or ALK rearrangements who have received prior adjuvant chemotherapy (NCCN.org). | detail... |
| CD274 positive | lung non-small cell carcinoma | predicted - sensitive | Niraparib + Pembrolizumab | Phase II | Actionable | In a Phase II trial, combination Zejula (niraparib) and Keytruda (pembrolizumab) resulted in an objective response rate (ORR) of 56.3% (9/16; 2 complete, 7 partial responses), 19.7-mo median duration of response (mDR), and 8.4-mo median progression-free survival (mPFS) in non-small cell lung cancer patients with a CD274 (PD-L1) TPS>=50%, and an ORR of 20% (4/20; 4 partial responses), 9.4-mo mDR, and 4.2-mo mPFS in patients with a CD274 (PD-L1) TPS=1-49% (PMID: 34478166; NCT03308942). | 34478166 | |
| CD274 positive | cervical cancer | sensitive | Nivolumab | Guideline | Actionable | Opdivo (nivolumab) is included in guidelines as second-line or subsequent therapy for patients with CD274 (PD-L1)-positive cervical cancer (NCCN.org). | detail... | |
| CD274 positive | sarcoma | predicted - sensitive | Doxorubicin + Pembrolizumab | Phase II | Actionable | In a Phase II trial, Keytruda (pembrolizumab) and Adriamycin (doxorubicin) combination treatment resulted in a greater overall response rate (63.6% vs 22.2%, p=0.048) in patients with metastatic or unresectable anthracycline-naive soft-tissue sarcomas with a CD274 (PD-L1) H-score >=5% compared to those with a H-score less than 5% (PMID: 34475102; NCT03056001). | 34475102 | |
| CD274 positive | triple-receptor negative breast cancer | sensitive | Atezolizumab + Nab-paclitaxel | Guideline | Actionable | The combination of Tecentriq (atezolizumab) and Abraxane (nab-paclitaxel) is included in guidelines as first line therapy for CD274 (PD-L1)-positive patients with triple-negative breast cancer (PMID: 34678411; ESMO.org). | 34678411 detail... | |
| CD274 positive | triple-receptor negative breast cancer | sensitive | Pembrolizumab | Pembrolizumab | Guideline | Actionable | The combination of Keytruda (pembrolizumab) plus chemotherapy such as Taxol (paclitaxel), Abraxane (nab-paclitaxel), or Paraplatin (carboplatin) plus Gemzar (gemcitabine) is included in guidelines as first line therapy for CD274 (PD-L1)-positive patients with triple-negative breast cancer (PMID: 34678411; ESMO.org). | detail... 34678411 |
| CD274 positive | colon cancer | sensitive | CS1003 | Preclinical | Actionable | In a preclinical study, CS1003 inhibited tumor growth in a xenograft model of CD274 (PD-L1)-positive colon cancer (PMID: 32467569). | 32467569 | |
| CD274 positive | transitional cell carcinoma | predicted - sensitive | Toripalimab-tpzi | Phase II | Emerging | In a Phase II trial (POLARIS-03), CD274 (PD-L1)-positive urothelial carcinoma patients (n=48) had an improved objective response rate (42% vs 17%, p=0.002) and median progression-free survival (3.7 months vs 1.8 months; p=0.001) compared to patients without CD274 (PD-L1) expression (n=96) following treatment with Loqtorz (toripalimab-tpzi) (PMID: 34740921; NCT03113266). | 34740921 | |
| CD274 positive | cervical squamous cell carcinoma | predicted - sensitive | Anlotinib + Sintilimab | Phase II | Actionable | In a Phase II study, a combination of Anlotinib (AL-3818) and Sintilimab (IBI308) resulted in a significantly higher objective response rate in CD274 (PD-L1)-positive cervical squamous cell carcinoma patients compared to non-squamous cell cervical cancer patients, 69.7% (23/33) versus 0% (0/6), respectively (P=0.003), and longer median progression-free survival, 11.1 months vs 5.8 months, respectively (P=0.01) (PMID: 35192397). | 35192397 | |
| CD274 positive | cervical cancer | predicted - sensitive | Anlotinib + Sintilimab | Phase II | Actionable | In a Phase II study, a combination of Anlotinib (AL-3818) and Sintilimab (IBI308) resulted in an objective response rate of 54.8% (23/42, 2 complete responses and 21 partial responses) in CD274 (PD-L1)-positive recurrent or metastatic cervical cancer patients, and led to a disease control rate of 88.1% (37/42, 14 with stable disease), a median progression-free survival (PFS) of 9.4 mos and a 6-mo PFS rate of 73.1%, a median overall survival (OS) not reached, and a 12-mo OS rate of 73.8% (PMID: 35192397). | 35192397 | |
| CD274 positive | cervical cancer | predicted - sensitive | Balstilimab + Zalifrelimab | Phase II | Actionable | In a Phase II study, a combination of Balstilimab (AGEN2034) and Zalifrelimab (AGEN1884) resulted in an objective response rate of 32.8% (22/67) in patients with recurrent and/or metastatic cervical cancer positive for CD274 (PD-L1) (PMID: 34932394; NCT03495882). | 34932394 | |
| CD274 positive | cervical adenocarcinoma | predicted - sensitive | Camrelizumab | Case Reports/Case Series | Actionable | In a clinical case study, Camrelizumab (SHR-1210) treatment resulted in a partial response in the cervical tumor and a complete response in the pulmonary metastases in a patient with CD274 (PD-L1)-positive (IHC = 1%) cervical adenocarcinoma, who previously progressed on chemotherapy treatment (PMID: 35280424). | 35280424 | |
| CD274 positive | ovarian cancer | predicted - sensitive | Pimivalimab | Case Reports/Case Series | Actionable | In a Phase I trial, Pimivalimab (JTX-4014) treatment led to a partial response lasting 232 days in a patient with CD274 (PD-L1)-positive (5% staining) ovarian cancer (PMID: 32989552; NCT03790488). | 32989552 | |
| CD274 positive | mucoepidermoid carcinoma | predicted - sensitive | Pimivalimab | Case Reports/Case Series | Actionable | In a Phase I trial, Pimivalimab (JTX-4014) treatment led to a complete response that was ongoing for at least 338 days in a patient with CD274 (PD-L1)-positive (60% staining) mucoepidermoid carcinoma of the parotid (PMID: 32989552; NCT03790488). | 32989552 | |
| CD274 positive | head and neck squamous cell carcinoma | sensitive | Pembrolizumab | Pembrolizumab | Guideline | Actionable | Keytruda (pembrolizumab) is included in the Pan-Asian Guidelines Adaptation (PAGA) for patients with CD274 (PD-L1)-positive (CPS >/=1) recurrent or metastatic head and neck squamous cell carcinoma (PMID: 34844180; ESMO.org). | detail... 34844180 |
| CD274 positive | head and neck squamous cell carcinoma | sensitive | Cisplatin + Fluorouracil + Pembrolizumab | Guideline | Actionable | Keytruda (pembrolizumab) in combination with platinum and Adrucil (fluorouracil) is included in the Pan-Asian Guidelines Adaptation (PAGA) for patients with CD274 (PD-L1)-positive (CPS >/=1) recurrent or metastatic head and neck squamous cell carcinoma (PMID: 34844180; ESMO.org). | detail... 34844180 | |
| CD274 positive | head and neck squamous cell carcinoma | sensitive | Carboplatin + Fluorouracil + Pembrolizumab | Guideline | Actionable | Keytruda (pembrolizumab) in combination with platinum and Adrucil (fluorouracil) is included in the Pan-Asian Guidelines Adaptation (PAGA) for patients with CD274 (PD-L1)-positive (CPS >/=1) recurrent or metastatic head and neck squamous cell carcinoma (PMID: 34844180; ESMO.org). | 34844180 detail... | |
| CD274 positive | stomach cancer | no benefit | Nivolumab + Paclitaxel | Phase II | Actionable | In a Phase II trial (K-Umbrella), Opdivo (nivolumab) and Taxol (paclitaxel) combination therapy improved median overall survival (10.7 vs 8.7 months, p=0.046) but not median progression-free survival (3.9 vs 4.0 months) in patients with advanced ERBB2 (HER2)-negative gastric cancer that was MSI high, mismatch repair deficient, or PD-L1 (CD274)-positive compared to standard of care in the control group (PMID: 37883723; NCT02951091). | 37883723 | |
| CD274 positive | ovarian carcinoma | predicted - sensitive | Durvalumab + Trabectedin | Case Reports/Case Series | Actionable | In a Phase Ib trial (TRAMUNE), Yondelis (trabectedin) plus Imfinzi (durvalumab) demonstrated safety and resulted in an objective response rate of 21.4% (3/14, all partial responses), 3- and 6-month progression-free rates of 42.9% and 42.9%, a 1-year progression-free survival (PFS) rate of 7.1%, and a 1-year overall survival rate of 57.1% in patients with ovarian carcinoma, with an improved PFS for patients with CD274 (PD-L1) expression (6.8 mo vs 1.3 mo) (PMID: 34965951; NCT03085225). | 34965951 | |
| CD274 positive | lung non-small cell carcinoma | predicted - sensitive | MT-6402 | Case Reports/Case Series | Actionable | In a Phase I trial, MT-6402 treatment led to an antitumor immune response and decreased metastatic bone lesions in a CD274 (PD-L1)-positive non-small cell lung cancer patient with osseous metastases (Cancer Res 2022;82(12_Suppl):Abstract nr CT152). | detail... | |
| CD274 positive | Advanced Solid Tumor | predicted - resistant | MT-6402 | Preclinical - Cell culture | Actionable | In a preclinical study, MT-6402 treatment demonstrated cytotoxicity in a panel of CD274 (PD-L1)-positive cancer cell lines in culture (Cancer Res 2022;82(12_Suppl):Abstract nr CT152). | detail... | |
| CD274 positive | Advanced Solid Tumor | sensitive | Acasunlimab | Preclinical | Actionable | In a preclinical study, Acasunlimab (GEN1046) treatment resulted in T-cell activation and proliferation and induced T-cell-mediated cytotoxicity of CD274 (PD-L1)-positive tumor cells in culture, and induced tumor regression in a transgenic mouse model expressing human CD274 (PD-L1) (PMID: 35176764). | 35176764 | |
| CD274 positive | ovary epithelial cancer | predicted - sensitive | Atezolizumab | Atezolizumab | Case Reports/Case Series | Actionable | In a Phase I trial, Tecentriq (atezolizumab) treatment resulted in an objective response rate (ORR) of 22.2% (2/9, 1 complete response, 1 partial response) and a median progression-free survival of 2.9 months in patients with advanced or recurrent ovarian epithelial cancer, ORR was 25% (2/8) in patients with tumor CD274 (PD-L1) expression of 5% or higher and 0% (0/1) in patients with tumor CD274 (PD-L1) expression below 5% (PMID: 31204078; NCT01375842). | 31204078 |
| CD274 positive | uterine cancer | predicted - sensitive | Atezolizumab | Atezolizumab | Case Reports/Case Series | Actionable | In a Phase I trial, Tecentriq (atezolizumab) treatment resulted in an objective response rate (ORR) of 13.3% (2/15, 2 partial responses) and a median progression-free survival of 1.4 months in patients with advanced or recurrent uterine cancer, ORR was 40% (2/5) in patients with tumor CD274 (PD-L1) expression of 5% or higher and 0% (0/10) in patients with tumor CD274 (PD-L1) expression below 5% (PMID: 31204078; NCT01375842). | 31204078 |
| CD274 positive | stomach cancer | sensitive | Nivolumab | Guideline | Actionable | Opdivo (nivolumab) in combination with fluoropyrimidine and platinum-based chemotherapy is included in guidelines as first-line therapy for patients with advanced, untreated gastric cancer expressing PD-L1 (CD274, CPS>=5) (PMID: 35914639; ESMO.org). | detail... 35914639 | |
| CD274 positive | gastroesophageal junction adenocarcinoma | sensitive | Nivolumab | Guideline | Actionable | Opdivo (nivolumab) in combination with fluoropyrimidine and platinum-based chemotherapy is included in guidelines as first-line therapy for patients with advanced, untreated gastroesophageal junction adenocacinoma expressing PD-L1 (CD274, CPS>=5) (PMID: 35914639; ESMO.org). | detail... 35914639 | |
| CD274 positive | esophageal cancer | sensitive | Nivolumab | Guideline | Actionable | Opdivo (nivolumab) in combination with fluoropyrimidine and platinum-based chemotherapy is included in guidelines as first-line therapy for patients with advanced, untreated esophageal cancer expressing PD-L1 (CD274, CPS>=5) (PMID: 35914639; ESMO.org). | 35914639 detail... | |
| CD274 positive | gastroesophageal junction adenocarcinoma | sensitive | Pembrolizumab | Pembrolizumab | Guideline | Actionable | Keytruda (pembrolizumab) is included in guidelines as first-line therapy for patients with advanced or metastatic gastroesophageal junction adenocarcinoma expressing PD-L1 (CD274, CPS>=10) (PMID: 35914639; ESMO.org). | 35914639 detail... |
| CD274 positive | esophagus adenocarcinoma | sensitive | Pembrolizumab | Pembrolizumab | Guideline | Actionable | Keytruda (pembrolizumab) is included in guidelines as first-line therapy for patients with advanced or metastatic esophageal adenocarcinoma expressing PD-L1 (CD274, CPS>=10) (PMID: 35914639; ESMO.org). | 35914639 detail... |
| CD274 positive | esophagus squamous cell carcinoma | sensitive | Pembrolizumab | Pembrolizumab | Guideline | Actionable | Keytruda (pembrolizumab) in combination with fluoropyrimidine and platinum-based chemotherapy is included in guidelines as first-line therapy for patients with advanced esophageal squamous carcinoma expressing PD-L1 (CD274, CPS>=10), and as second or subsequent lines of treatment for previously treated patients who have not received immunotherapy and with CPS>=10 (PMID: 35914638; ESMO.org). | detail... 35914638 |
| CD274 positive | esophagus squamous cell carcinoma | sensitive | Nivolumab | Guideline | Actionable | Opdivo (nivolumab) in combination with fluoropyrimidine and platinum-based chemotherapy is included in guidelines as first-line therapy for patients with advanced esophageal squamous carcinoma expressing PD-L1 (CD274, TPS>=1%) (PMID: 35914638; ESMO.org). | detail... 35914638 | |
| CD274 positive | esophagus squamous cell carcinoma | sensitive | Ipilimumab + Nivolumab | Ipilimumab + Nivolumab | Guideline | Actionable | Yervoy (ipilimumab) in combination with Opdivo (nivolumab) is included in guidelines as first-line therapy for patients with advanced esophageal squamous carcinoma expressing PD-L1 (CD274, TPS>=1%) (PMID: 35914638; ESMO.org). | 35914638 detail... |
| CD274 positive | melanoma | predicted - sensitive | Cetrelimab | Phase Ib/II | Actionable | In a Phase I/II trial, Cetrelimab (JNJ-63723283) treatment demonstrated safety, and resulted in an overall response rate (ORR) of 18.6% (38/204), clinical benefit rate (CBR) of 31.3% (64/204), median progression-free survival (mPFS) of 2.8 mo, and median overall survival (mOS) of 17.8 mo in advanced solid tumor patients, with an ORR of 50% (4/8, 1 complete and 3 partial responses), and CBR of 75% (6/8) in CD274 (PD-L1)-positive melanoma patients (PMID: 35298698; NCT02908906). | 35298698 | |
| CD274 positive | lung adenocarcinoma | sensitive | Ipilimumab + Nivolumab | Ipilimumab + Nivolumab | Guideline | Actionable | Combination Opdivo (nivolumab) plus Yervoy (ipilimumab) is in guidelines as first-line therapy (category 1) for advanced or metastatic lung adenocarcinoma patients with CD274 (PD-L1) expression >1% and negative for actionable molecular biomarkers (NCCN.org). | detail... |
| CD274 positive | lung large cell carcinoma | sensitive | Ipilimumab + Nivolumab | Ipilimumab + Nivolumab | Guideline | Actionable | Combination Opdivo (nivolumab) plus Yervoy (ipilimumab) is in guidelines as first-line therapy (category 1) for advanced or metastatic large cell lung cancer patients with CD274 (PD-L1) expression >1% and negative for actionable molecular biomarkers (NCCN.org). | detail... |
| CD274 positive | lung squamous cell carcinoma | sensitive | Ipilimumab + Nivolumab | Ipilimumab + Nivolumab | Guideline | Actionable | Combination Opdivo (nivolumab) plus Yervoy (ipilimumab) is in guidelines as first-line therapy (category 1) for advanced or metastatic lung squamous cell carcinoma patients with CD274 (PD-L1) expression >1% and negative for actionable molecular biomarkers (NCCN.org). | detail... |
| CD274 positive | lung non-small cell carcinoma | sensitive | Carboplatin + Durvalumab + Nab-paclitaxel + Tremelimumab | Guideline | Actionable | Combination Paraplatin (carboplatin), Abraxane (nab-paclitaxel), Imfinzi (durvalumab), and Imjudo (tremelimumab) is in guidelines as first-line therapy (category 1) for patients with advanced or metastatic non-small cell lung cancer, not otherwise specified, with CD274 (PD-L1) expression of 1% to 49%, and negative for actionable molecular biomarkers (NCCN.org). | detail... | |
| CD274 positive | lung large cell carcinoma | sensitive | Carboplatin + Durvalumab + Nab-paclitaxel + Tremelimumab | Guideline | Actionable | Combination Paraplatin (carboplatin), Abraxane (nab-paclitaxel), Imfinzi (durvalumab), and Imjudo (tremelimumab) is in guidelines as first-line therapy (category 1) for patients with advanced or metastatic large cell lung cancer, with CD274 (PD-L1) expression of 1% to 49%, and negative for actionable molecular biomarkers (NCCN.org). | detail... | |
| CD274 positive | lung adenocarcinoma | sensitive | Carboplatin + Durvalumab + Nab-paclitaxel + Tremelimumab | Guideline | Actionable | Combination Paraplatin (carboplatin), Abraxane (nab-paclitaxel), Imfinzi (durvalumab), and Imjudo (tremelimumab) is in guidelines as first-line therapy (category 1) for patients with advanced or metastatic lung adenocarcinoma, with CD274 (PD-L1) expression of 1% to 49%, and negative for actionable molecular biomarkers (NCCN.org). | detail... | |
| CD274 positive | lung non-small cell carcinoma | sensitive | Carboplatin + Durvalumab + Pemetrexed Disodium + Tremelimumab | Guideline | Actionable | Combination Paraplatin (carboplatin), Alimta (pemetrexed disodium), Imfinzi (durvalumab), and Imjudo (tremelimumab) is in guidelines as first-line therapy (category 1) for patients with advanced or metastatic non-small cell lung cancer, not otherwise specified, with CD274 (PD-L1) expression of 1% to 49%, and negative for actionable molecular biomarkers (NCCN.org). | detail... | |
| CD274 positive | lung adenocarcinoma | sensitive | Carboplatin + Durvalumab + Pemetrexed Disodium + Tremelimumab | Guideline | Actionable | Combination Paraplatin (carboplatin), Alimta (pemetrexed disodium), Imfinzi (durvalumab), and Imjudo (tremelimumab) is in guidelines as first-line therapy (category 1) for patients with advanced or metastatic lung adenocarcinoma with CD274 (PD-L1) expression of 1% to 49%, and negative for actionable molecular biomarkers (NCCN.org). | detail... | |
| CD274 positive | lung large cell carcinoma | sensitive | Carboplatin + Durvalumab + Pemetrexed Disodium + Tremelimumab | Guideline | Actionable | Combination Paraplatin (carboplatin), Alimta (pemetrexed disodium), Imfinzi (durvalumab), and Imjudo (tremelimumab) is in guidelines as first-line therapy (category 1) for patients with advanced or metastatic large cell lung cancer, with CD274 (PD-L1) expression of 1% to 49%, and negative for actionable molecular biomarkers (NCCN.org). | detail... | |
| CD274 positive | lung adenocarcinoma | sensitive | Cisplatin + Durvalumab + Pemetrexed Disodium + Tremelimumab | Guideline | Actionable | Combination Platinol (cisplatin), Alimta (pemetrexed disodium), Imfinzi (durvalumab), and Imjudo (tremelimumab) is in guidelines as first-line therapy (category 1) for patients with advanced or metastatic lung adenocarcinoma with CD274 (PD-L1) expression of 1% to 49%, and negative for actionable molecular biomarkers (NCCN.org). | detail... | |
| CD274 positive | lung non-small cell carcinoma | sensitive | Cisplatin + Durvalumab + Pemetrexed Disodium + Tremelimumab | Guideline | Actionable | Combination Platinol (cisplatin), Alimta (pemetrexed disodium), Imfinzi (durvalumab), and Imjudo (tremelimumab) is in guidelines as first-line therapy (category 1) for patients with advanced or metastatic non-small cell lung cancer, not otherwise specified, with CD274 (PD-L1) expression of 1% to 49%, and negative for actionable molecular biomarkers (NCCN.org). | detail... | |
| CD274 positive | lung large cell carcinoma | sensitive | Cisplatin + Durvalumab + Pemetrexed Disodium + Tremelimumab | Guideline | Actionable | Combination Platinol (cisplatin), Alimta (pemetrexed disodium), Imfinzi (durvalumab), and Imjudo (tremelimumab) is in guidelines as first-line therapy (category 1) for patients with advanced or metastatic large cell lung cancer, with CD274 (PD-L1) expression of 1% to 49%, and negative for actionable molecular biomarkers (NCCN.org). | detail... | |
| CD274 positive | osteosarcoma | predicted - sensitive | ZKAB001 | Case Reports/Case Series | Actionable | In a Phase I/II trial, ZKAB001 treatment resulted in improved 6, 12, and 24-month event-free survival (100%) in osteosarcoma patients with CD274 (PD-L1) expression (TPS >/= 1%) compared to a 6-month EFS of 84.5% and 12 and 24-month EFS of 64.7% in patients without CD274 (PD-L1) expression (PMID: 36469563). | 36469563 | |
| CD274 positive | biliary tract cancer | sensitive | Nivolumab | Phase II | Actionable | In a Phase II trial, baseline CD274 (PD-L1) expression was associated with increased median progression-free survival (PFS) in biliary tract cancer patients treated with Opdivo (nivolumab) compared to patients without CD274 (PD-L1) expression, with a median PFS of 19.8 months vs 2.4 months (P=0.0001) and 12-month PFS rate of 61% vs 5%, respectively (PMID: 36252287; NCT02829918). | 36252287 | |
| CD274 positive | esophagus squamous cell carcinoma | predicted - sensitive | Cisplatin + Paclitaxel + Toripalimab-tpzi | Phase III | Actionable | In a post hoc analysis of a Phase III trial (JUPITER-06), addition of Loqtorz (toripalimab-tpzi) to paclitaxel and cisplatin improved progression-free survival (5.7 vs 5.5 mo, HR 0.59, p=0.0005 TPS H; 6.1 vs 5.7 mo, HR 0.59, p=0.0089 TPS L) and median overall survival (16.9 vs 10.8 mo, HR=0.61, p=0.0133 TPS H; not reached vs 11.6 mo, HR=0.63, p=0.0913 TPS L) in patients with esophagus squamous cell carcinoma with low (L, TPS<1%) or high (H, TPS>=1%) CD274 (PD-L1) expression (PMID: 36473145). | 36473145 | |
| CD274 positive | esophagus squamous cell carcinoma | sensitive | Capecitabine + Cisplatin + Pembrolizumab | Guideline | Actionable | Keytruda (pembrolizumab) in combination with first-line chemotherapy including Xeloda (capecitabine) and Platinol (cisplatin) is included in guidelines as preferred first-line therapy for patients with locally advanced, recurrent, or metastatic esophageal squamous cell carcinoma expressing PD-L1 (CD274) with CPS >/= 10 (category 1) and for patients with CPS <10 (category 2B) (NCCN.org). | detail... | |
| CD274 positive | esophagus squamous cell carcinoma | sensitive | Cisplatin + Fluorouracil + Pembrolizumab | Guideline | Actionable | Keytruda (pembrolizumab) in combination with first-line chemotherapy including Adrucil (fluorouracil) and Platinol (cisplatin) is included in guidelines as preferred first-line therapy for patients with locally advanced, recurrent, or metastatic esophageal squamous cell carcinoma expressing PD-L1 (CD274) with CPS >/= 10 (category 1) and for patients with CPS <10 (category 2B) (NCCN.org). | detail... | |
| CD274 positive | esophagus squamous cell carcinoma | sensitive | Fluorouracil + Oxaliplatin + Pembrolizumab | Guideline | Actionable | Keytruda (pembrolizumab) in combination with first-line chemotherapy including Adrucil (fluorouracil) and Eloxatin (oxaliplatin) is included in guidelines as preferred first-line therapy for patients with locally advanced, recurrent, or metastatic esophageal squamous cell carcinoma expressing PD-L1 (CD274) with CPS >/= 10 (category 1) and for patients with CPS <10 (category 2B) (NCCN.org). | detail... | |
| CD274 positive | esophagus squamous cell carcinoma | sensitive | Capecitabine + Oxaliplatin + Pembrolizumab | Guideline | Actionable | Keytruda (pembrolizumab) in combination with first-line chemotherapy including Xeloda (capecitabine) and Eloxatin (oxaliplatin) is included in guidelines as preferred first-line therapy for patients with locally advanced, recurrent, or metastatic esophageal squamous cell carcinoma expressing PD-L1 (CD274) with CPS >/= 1 (category 1) (NCCN.org). | detail... | |
| CD274 positive | gastroesophageal junction adenocarcinoma | sensitive | Fluorouracil + Nivolumab + Oxaliplatin | Guideline | Actionable | Opdivo (nivolumab) in combination with first-line chemotherapy including Adrucil (fluorouracil) and Eloxatin (oxaliplatin) is included in guidelines as preferred first-line therapy for patients with locally advanced, recurrent, or metastatic gastroesophageal junction adenocarcinoma expressing CD274 (PD-L1) with CPS >/= 1 (category 1 for CPS >/= 5) and without ERBB2 (HER2) overexpression (NCCN.org). | detail... | |
| CD274 positive | gastroesophageal junction adenocarcinoma | sensitive | Capecitabine + Nivolumab + Oxaliplatin | Guideline | Actionable | Opdivo (nivolumab) in combination with first-line chemotherapy including Xeloda (capecitabine) and Eloxatin (oxaliplatin), is included in guidelines as preferred first-line therapy for patients with locally advanced, recurrent, or metastatic gastroesophageal junction adenocarcinoma expressing CD274 (PD-L1) with CPS >/= 1 (category 1 for CPS >/= 5) and without ERBB2 (HER2) overexpression (NCCN.org). | detail... | |
| CD274 positive | esophagus adenocarcinoma | sensitive | Capecitabine + Nivolumab + Oxaliplatin | Guideline | Actionable | Opdivo (nivolumab) in combination with first-line chemotherapy including Xeloda (capecitabine) and Eloxatin (oxaliplatin), is included in guidelines as preferred first-line therapy for patients with locally advanced, recurrent, or metastatic esophageal adenocarcinoma expressing CD274 (PD-L1) with CPS >/= 1 (category 1 for CPS >/= 5) and without ERBB2 (HER2) overexpression (NCCN.org). | detail... | |
| CD274 positive | esophagus adenocarcinoma | sensitive | Fluorouracil + Nivolumab + Oxaliplatin | Guideline | Actionable | Opdivo (nivolumab) in combination with first-line chemotherapy including Adrucil (fluorouracil) and Eloxatin (oxaliplatin) is included in guidelines as preferred first-line therapy for patients with locally advanced, recurrent, or metastatic esophageal adenocarcinoma expressing CD274 (PD-L1) with CPS >/= 1 (category 1 for CPS >/= 5) and without ERBB2 (HER2) overexpression (NCCN.org). | detail... | |
| CD274 positive | head and neck squamous cell carcinoma | no benefit | Ipilimumab + Nivolumab | Ipilimumab + Nivolumab | Phase III | Actionable | In a Phase III trial (CheckMate 651), first-line Opdivo (nivolumab) plus Yervoy (ipilimumab) treatment did not improve overall survival (17.6 vs 14.6 mo; HR=0.78) or objective response rate (34.1 vs 36.0%) compared to EXTREME (Erbitux (cetuximab) plus Platinol (cisplatin) or Paraplatin (carboplatin) plus Adrucil (fluorouracil) followed by Erbitux (cetuximab) maintenance) in recurrent/metastatic CD274 (PD-L1)-positive (CPS>=20) head and neck squamous cell carcinoma patients (PMID: 36473143; NCT02741570). | 36473143 |
| CD274 positive | lung non-small cell carcinoma | predicted - sensitive | Surufatinib + Toripalimab-tpzi | Phase II | Actionable | In a Phase II trial, Surufatinib (HMPL-012) plus Loqtorz (toripalimab-tpzi) treatment resulted in an objective response rate of 57.1%, a disease control rate of 100%, a median duration of response of 8.31 months, a median progression-free survival of 9.63 months, a median overall survival (OS) that was not reached, and a 12-month OS rate of 64% in patients with CD274 (PD-L1)-positive (TPS>=1%) non-small cell lung cancer (Cancer Res (2023) 83 (8_Supplement): CT225; NCT04169672). | detail... | |
| CD274 positive | lung non-small cell carcinoma | predicted - sensitive | AZD2936 | Phase I | Actionable | In a Phase I trial (ARTEMIDE-01), AZD2936 treatment demonstrated acceptable safety and activity in patients with CD274 (PD-L1)-positive (TPS >/= 1%) advanced non-small cell lung cancer, with an overall response rate of 3.9% (3/76, 3 partial responses), stable disease in 39.5% (30/76), disease control rate (DCR) at 9 weeks of 43.4% (33/76), and a DCR at 27 weeks of 14.5% (11/76), with a duration of response of 2.1-6.4 mo (J Clin Oncol 41, 2023 (suppl 16; abstr 9050); NCT04995523). | detail... | |
| CD274 positive | Advanced Solid Tumor | predicted - sensitive | PF-07257876 | Phase I | Actionable | In a Phase I trial, PF-07257876 treatment was well tolerated in patients with PD-L1 (CD274)-positive advanced solid tumors and resulted in an objective response rate of 5.6% (1/18, 1 partial response in a patient with head and neck squamous cell carcinoma) (J Clin Oncol 41, 2023 (suppl 16; abstr 2529); NCT04881045). | detail... | |
| CD274 positive | Advanced Solid Tumor | predicted - sensitive | KN046 | Phase I | Actionable | In a Phase I trial, KN046 treatment was well tolerated and resulted in an objective response rate of 12.5% (11/88; all partial responses) and median duration of response of 16.6 months in patients with advanced solid tumors, patients with CD274 (PD-L1)-positive tumors experienced longer median progression-free survival (2.5 vs 1.3 months, p=0.0098) and overall survival (19.9 vs 5.4 months, p=0.014) than those with CD274 (PD-L1)-negative tumors ( (PMID: 37263673; NCT03733951). | 37263673 | |
| CD274 positive | ovary epithelial cancer | no benefit | Atezolizumab + Bevacizumab + Carboplatin + Pegylated liposomal doxorubicin | Phase III | Actionable | In a Phase III trial (ATALANTE/ENGOT-ov29), Avastin (bevacizumab) combined with platinum-based chemotherapy (carboplatin plus gemcitabine, doxil, or paclitaxel) plus Tecentriq (atezolizumab) vs placebo did not meet the primary progression-free survival (PFS) objective in CD274 (PD-L1)-positive epithelial ovarian cancer patients, with a median PFS of 15.2 vs 13.1 mo (HR=0.86, P=0.30), and resulted in a median overall survival of 40.7 vs 33.6 mo (HR=0.90), respectively (PMID: 37643382; NCT02891824). | 37643382 | |
| CD274 positive | lung non-small cell carcinoma | predicted - sensitive | Atezolizumab + Tiragolumab | Phase I | Actionable | In a Phase Ia/Ib trial (GO30103), treatment with the combination of Tecentriq (atezolizumab) and Tiragolumab (MTIG7192A) demonstrated safety and efficacy in patients with CD274 (PD-L1)-positive (>/=1%) immunotherapy-naive metastatic non-small cell lung cancer, resulting in an objective response rate of 46% (6/13, 2 complete and 4 partial responses), a disease control rate of 77% (10/13), and a duration of response of 24.2 months (PMID: 37768658; NCT02794571). | 37768658 | |
| CD274 positive | renal cell carcinoma | predicted - sensitive | Nivolumab | Phase II | Actionable | In a Phase II trial (HCRN GU16-260), Opdivo (nivolumab) treatment in patients with CD274 (PD-L1)-positive treatment-naive advanced clear cell renal cell carcinoma resulted in an objective response rate (ORR) 50% (8/16) in patients with CD274 (PD-L1) expression between 1% to 20% and an ORR of 75% (6/8), median progression-free survival (PFS) of 20.6 months, and 1-year PFS rate of 75% in patients with CD274 (PD-L1) expression of 20% or higher (PMID: 35442713; NCT03117309). | 35442713 | |
| CD274 positive | head and neck squamous cell carcinoma | predicted - sensitive | IO102-IO103 + Pembrolizumab | Case Reports/Case Series | Actionable | In a Phase II trial, treatment with the combination of IO102-IO103 and Keytruda (pembrolizumab) demonstrated safety and resulted in a partial response in 50% (2/4, 1 confirmed partial response) in patients with squamous cell carcinoma of the head and neck with CD274 (PD-L1) expression (combined positive scores >/=20) (Ann Oncol (2023) 34 (suppl_2): S630; NCT05077709). | detail... | |
| CD274 positive | endometrial cancer | predicted - sensitive | Carboplatin + Durvalumab + Paclitaxel | Phase III | Actionable | In a Phase III trial (DUO-E), Imfinzi (durvalumab) plus platinum therapy (carboplatin/paclitaxel) followed by Imfinzi (durvalumab) with (n=150) or without Lynparza (olaparib) (n=170) maintenance resulted in an improved progression-free survival compared to platinum therapy + placebo followed by placebo maintenance (n=163) (HR=0.42 with olaparib, HR=0.63 without olaparib) in a subgroup of CD274 (PD-L1)-positive patients with advanced or recurrent endometrial cancer (PMID: 37864337; NCT04269200). | 37864337 | |
| CD274 positive | triple-receptor negative breast cancer | predicted - sensitive | Nab-paclitaxel + Toripalimab-tpzi | Phase III | Actionable | In a Phase III trial (TORCHLIGHT), treatment with Loqtorz (toripalimab-tpzi) plus Abraxane (nab-paclitaxel) demonstrated safety and led to an improved median progression-free survival (mPFS) compared to nab-paclitaxel plus placebo in CD274 (PD-L1)-positive (CPS >/= 1) triple-negative breast cancer patients, with a mPFS of 8.4 vs 5.6 mo (HR=0.65, p=0.0102) and in the intention to treat population, a mPFS of 8.4 vs 6.9 mo (PMID: 38191615; NCT03777579, NCT04085276). | 38191615 | |
| CD274 positive | colon cancer | sensitive | CTX-8371 | Preclinical | Actionable | In a preclinical study, CTX-8371 treatment resulted in greater tumor growth inhibition than either Keytruda (pembrolizumab) or Tecentriq (atezolizumab) in a syngeneic mouse model of colon cancer expressing CD274 (PD-L1), with tumor regression in 62.5% (5/8) of the treated mouse models (PMID: 38379869). | 38379869 | |
| CD274 positive | melanoma | sensitive | CTX-8371 | Preclinical | Actionable | In a preclinical study, CTX-8371 treatment resulted in fewer lung metastases than either Keytruda (pembrolizumab) or Tecentriq (atezolizumab) monotherapy in a syngeneic mouse model of melanoma expressing CD274 (PD-L1) (PMID: 38379869). | 38379869 | |
| CD274 positive | esophagus squamous cell carcinoma | predicted - sensitive | Cisplatin + Fluorouracil + Sugemalimab | Phase III | Actionable | In a Phase III trial (GEMSTONE-304), treatment with Sugemalimab (CS1001) combined with chemotherapy (Platinol (cisplatin) and Adrucil (fluorouracil)) demonstrated safety in patients with esophagus squamous cell carcinoma (n=358), and in CD274 (PD-L1)-positive patients (IHC >=10%, n=154), resulted in improved median progression-free survival (7.0 vs 5.4 mo, HR=0.50) and median overall survival (15.7 vs 11.2 mo, HR=0.57) compared to the placebo plus chemotherapy cohort (n=78) (PMID: 38302715; NCT04187352). | 38302715 | |
| CD274 positive | esophagus adenocarcinoma | sensitive | Capecitabine + Cisplatin + Pembrolizumab | Guideline | Actionable | Keytruda (pembrolizumab) in combination with first-line chemotherapy including Xeloda (capecitabine) and Platinol (cisplatin) is included in guidelines as preferred first-line therapy for patients with locally advanced, recurrent, or metastatic ERBB2 (HER2) overexpression-negative esophageal adenocarcinoma expressing PD-L1 (CD274) with CPS >/= 10 (category 1) or with CPS >/= 1 and <10 (category 2B) (NCCN.org). | detail... | |
| CD274 positive | esophagus adenocarcinoma | sensitive | Capecitabine + Oxaliplatin + Pembrolizumab | Guideline | Actionable | Keytruda (pembrolizumab) in combination with first-line chemotherapy including Xeloda (capecitabine) and Eloxatin (oxaliplatin) is included in guidelines as preferred first-line therapy for patients with locally advanced, recurrent, or metastatic esophageal adenocarcinoma expressing CD274 (PD-L1) with CPS >/= 1 (category 1 for CPS >/= 5) and without ERBB2 (HER2) overexpression (NCCN.org). | detail... | |
| CD274 positive | esophagus adenocarcinoma | sensitive | Cisplatin + Fluorouracil + Pembrolizumab | Guideline | Actionable | Keytruda (pembrolizumab) in combination with first-line chemotherapy including Adrucil (fluorouracil) and Platinol (cisplatin) is included in guidelines as preferred first-line therapy for patients with locally advanced, recurrent, or metastatic ERBB2 (HER2) overexpression-negative esophageal adenocarcinoma expressing PD-L1 (CD274) with CPS >/= 10 (category 1) or with CPS >/= 1 and <10 (category 2B) (NCCN.org). | detail... | |
| CD274 positive | esophagus adenocarcinoma | sensitive | Fluorouracil + Oxaliplatin + Pembrolizumab | Guideline | Actionable | Keytruda (pembrolizumab) in combination with first-line chemotherapy including Adrucil (fluorouracil) and Eloxatin (oxaliplatin), is included in guidelines as preferred first-line therapy for patients with with locally advanced, recurrent, or metastatic ERBB2 (HER2) overexpression-negative esophageal adenocarcinoma expressing PD-L1 (CD274) with CPS >/= 10 (category 1) or with CPS >/= 1 and <10 (category 2B) (NCCN.org). | detail... | |
| CD274 positive | vaginal carcinoma | sensitive | Nivolumab | Guideline | Actionable | Opdivo (nivolumab) is included in guidelines as second-line or subsequent therapy for patients with recurrent or metastatic vaginal squamous cell carcinoma or adenocarcinoma with CD274 (PD-L1) expression (CPS >/= 1) (NCCN.org). | detail... | |
| CD274 positive | vaginal carcinoma | sensitive | Pembrolizumab | Pembrolizumab | Guideline | Actionable | Keytruda (pembrolizumab) is included in guidelines as preferred second-line or subsequent therapy for patients with recurrent or metastatic vaginal squamous cell carcinoma or adenocarcinoma with CD274 (PD-L1) expression (CPS >/= 1) (NCCN.org). | detail... |
| CD274 positive | vaginal carcinoma | sensitive | Bevacizumab + Cisplatin + Paclitaxel + Pembrolizumab | Guideline | Actionable | Keytruda (pembrolizumab) in combination with Platinol (cisplatin), Taxol (paclitaxel), and Avastin (bevacizumab) is included in guidelines as preferred first-line therapy for patients with recurrent or metastatic vaginal squamous cell carcinoma or adenocarcinoma with CD274 (PD-L1) expression (CPS >/= 1) (NCCN.org). | detail... | |
| CD274 positive | vaginal carcinoma | sensitive | Cisplatin + Paclitaxel + Pembrolizumab | Guideline | Actionable | Keytruda (pembrolizumab) in combination with Platinol (cisplatin) and Taxol (paclitaxel) is included in guidelines as preferred first-line therapy for patients with recurrent or metastatic vaginal squamous cell carcinoma or adenocarcinoma with CD274 (PD-L1) expression (CPS >/= 1) (NCCN.org). | detail... | |
| CD274 positive | vaginal carcinoma | sensitive | Carboplatin + Paclitaxel + Pembrolizumab | Guideline | Actionable | Keytruda (pembrolizumab) in combination with Paraplatin (carboplatin) and Taxol (paclitaxel) is included in guidelines as preferred first-line therapy for patients with recurrent or metastatic vaginal squamous cell carcinoma or adenocarcinoma with CD274 (PD-L1) expression (CPS >/= 1) (NCCN.org). | detail... | |
| CD274 positive | triple-receptor negative breast cancer | no benefit | Atezolizumab + Carboplatin + Gemcitabine | Phase III | Actionable | In a Phase III trial (Impassion132), the addition of Tecentriq (atezolizumab) to Xeloda (capecitabine) or Paraplatin (carboplatin) plus Gemzar (gemcitabine) treatment did not improve efficacy in early relapsing, unresectable, advanced CD274 (PD-L1)-positive triple-negative breast cancer patients, with median overall survival of 12.1 vs. 11.2 mo (HR=0.93, p=0.59), median progression-free survival of 4.2 vs. 3.6 mo, and objective response rates of 40% (61/177) vs. 28% (45/177) (PMID: 38755096; NCT03371017). | 38755096 | |
| CD274 positive | triple-receptor negative breast cancer | no benefit | Atezolizumab + Capecitabine | Phase III | Actionable | In a Phase III trial (Impassion132), the addition of Tecentriq (atezolizumab) to Xeloda (capecitabine) or Paraplatin (carboplatin) plus Gemzar (gemcitabine) treatment did not improve efficacy in early relapsing, unresectable, advanced CD274 (PD-L1)-positive triple-negative breast cancer patients, with median overall survival of 12.1 vs. 11.2 mo (HR=0.93, p=0.59), median progression-free survival of 4.2 vs. 3.6 mo, and objective response rates of 40% (61/177) vs. 28% (45/177) (PMID: 38755096; NCT03371017). | 38755096 | |
| CD274 positive | lung non-small cell carcinoma | predicted - sensitive | Cemiplimab | Phase III | Actionable | In a Phase III trial (EMPOWER-Lung 3), first-line Libtayo (cemiplimab) and platinum-doublet chemotherapy combination treatment (n=217) significantly improved median overall survival (23.5 vs 12.1 mo, HR=0.51, p<0.0001) and median progression-free survival (8.3 vs 5.5 mo, HR=0.48, p<0.0001) compared to chemotherapy and placebo (n=110) in patients with advanced non-small cell lung cancer with CD274 (PD-L1) expression >/= 1% and without EGFR, ALK, or ROS1 aberrations (PMID: 38820979; NCT03409614). | 38820979 | |
| CD274 positive | colorectal cancer | predicted - sensitive | IBI363 | Phase I | Actionable | In a Phase I trial, IBI363 treatment demonstrated safety in patients with advanced or metastatic CD274 (PD-L1)-positive (CPS>=1) colorectal cancer who had failed on or were intolerant to standard therapy (n=13) and resulted in an objective response rate of 30.8% and disease control rate of 76.9% (J Clin Oncol 42, 2024 (suppl 16; abstr 2504); NCT05460767). | detail... | |
| CD274 positive | oropharynx cancer | predicted - sensitive | Cemiplimab + ISA101b | Phase II | Actionable | In a Phase II trial, ISA101b and Libtayo (cemiplimab) combination treatment demonstrated safety in patients with HPV16-positive oropharynx cancer and resulted in an overall response rate (ORR) that did not significantly differ from placebo plus Libtayo (cemiplimab) in the full analysis set (25.3 vs 22.9%, p=0.590), but in CD274 (PD-L1)-positive patients in the per protocol set (CPS>/=20), the ORR was significantly improved (61.9 vs 28.0%, p=0.026) (J Clin Oncol 42, 2024 (suppl 16; abstr 6003); NCT03669718). | detail... | |
| CD274 positive | Advanced Solid Tumor | predicted - sensitive | MCLA-145 | Phase I | Actionable | In a Phase I trial, MCLA-145 treatment demonstrated safety and activity in patients with CD274 (PD-L1)-positive advanced solid tumors (n=52), resulting in 5 partial responses (1 each in glioblastoma, sarcoma, cervical cancer, anal cancer, and gastric cancer) and a disease control rate of 37% (J Clin Oncol 42, 2024 (suppl 16; abstr 2520); NCT03922204). | detail... | |
| CD274 positive | Advanced Solid Tumor | predicted - sensitive | MCLA-145 + Pembrolizumab | Phase I | Actionable | In a Phase I trial, treatment with the combination of MCLA-145 and Keytruda (pembrolizumab) demonstrated safety and activity in patients with CD274 (PD-L1)-positive advanced solid tumors (n=19), resulting in 1 complete response in a patient with non-small cell lung cancer and 1 partial response in a patient with Merkel cell carcinoma, and a disease control rate of 68% (J Clin Oncol 42, 2024 (suppl 16; abstr 2520); NCT03922204). | detail... | |
| CD274 positive | Advanced Solid Tumor | predicted - sensitive | SGN-PDL1V | Phase I | Actionable | In a Phase I trial, SGN-PDL1V treatment demonstrated manageable safety and resulted in an objective response rate of 27.3% and a median duration of response of 7.9 months in patients with CD274-positive advanced solid tumors (n=55), including non-small cell lung cancer, head and neck squamous cell carcinoma, triple-negative breast cancer, and esophageal cancer (Ann Oncol (2024) 35 (suppl_2): S486;NCT05208762). | detail... | |
| CD274 positive | head and neck squamous cell carcinoma | predicted - sensitive | MK-7684A | Phase II | Actionable | In a Phase II trial (KEYVIBE-005), MK-7684A treatment resulted in an objective response rate (ORR) of 29% (12/42), a median duration of response of 12.7 months, a median progression survival of 4.1 months, and a median overall survival of 15.5 months in patients with CD274 (PD-L1)-positive (CPS>/=1) head and neck squamous cell carcinoma, with an ORR of 21% (5/24) in patients with CPS=1-19 and an ORR of 41% with CPS>/=20 (Ann Oncol (2024) 35 (Suppl_2): S617-S618; NCT05007106). | detail... | |
| CD274 positive | lung non-small cell carcinoma | predicted - sensitive | Durvalumab | Phase II | Actionable | In a Phase II trial (SAVIMMUNE), Imfinzi (durvalumab) treatment demonstrated safety and resulted in an 8-week objective response rate (ORR) of 26%, and 16-week ORR of 24%, median progression-free survival of 2.3 months, median overall survival (OS) of 6.9 months, a 12-month OS rate of 40%, and a median duration of response of 11.3 months in patients with advanced CD274 (PD-L1)-positive (TPS >/=25%) non-small cell lung cancer with a performance score of 2 or 3 (Ann Oncol (2024) 35 (suppl_2): S842). | detail... | |
| CD274 positive | cervical cancer | sensitive | Pembrolizumab + Tisotumab vedotin-tftv | Guideline | Actionable | Keytruda (pembrolizumab) combined with Tivdak (tisotumab vedotin-tftv) is included in guidelines as second-line or subsequent therapy for patients with recurrent or metastatic cervical cancer expressing CD274 (PD-L1, CPS>/=1) (NCCN.org). | detail... | |
| CD274 positive | vulva adenocarcinoma | sensitive | Pembrolizumab | Pembrolizumab | Guideline | Actionable | Keytruda (pembrolizumab) is included in guidelines as a second-line or subsequent therapy for patients with advanced or recurrent/metastatic CD274 (PD-L1)-positive (CPS >= 1) vulvar adenocarcinoma (NCCN.org). | detail... |
| CD274 positive | vulva squamous cell carcinoma | sensitive | Pembrolizumab | Pembrolizumab | Guideline | Actionable | Keytruda (pembrolizumab) is included in guidelines as a second-line or subsequent therapy for patients with advanced or recurrent/metastatic CD274 (PD-L1)-positive (CPS >= 1) vulvar squamous cell carcinoma (NCCN.org). | detail... |
| CD274 positive | lung non-small cell carcinoma | predicted - sensitive | Pembrolizumab + Ramucirumab | Phase II | Actionable | In a Phase II trial (EAST ENERGY), neoadjuvant treatment with Cyramza (ramucirumab) plus Keytruda (pembrolizumab) demonstrated safety and activity in patients with CD274 (PD-L1)-positive (IHC>=1%) non-small cell lung cancer, with a major pathologic response rate of 50.0% (12/24), pathologic complete response rate of 25.0% (6/24), objective response rate of 29.2% (7/24, all partial responses), 2-year overall survival rate of 95.7%, and 2-year relapse-free survival rate of 82.6% (PMID: 39453771; NCT04040361). | 39453771 | |
| CD274 positive | salivary gland cancer | sensitive | Pembrolizumab | Pembrolizumab | Guideline | Actionable | Keytruda (pembrolizumab) is included in guidelines for patients with CD274 (PD-L1)-positive recurrent, unresectable, or metastatic salivary gland tumors (NCCN.org). | detail... |
| CD274 positive | oral cavity cancer | sensitive | Pembrolizumab | Pembrolizumab | Guideline | Actionable | Keytruda (pembrolizumab) is included in guidelines as neoadjuvant (category 2A) and first-line therapy (category 1) for patients with CD274 (PD-L1)-positive (CPS >= 1) recurrent, unresectable, or metastatic oral cavity cancer (NCCN.org). | detail... |
| CD274 positive | oropharynx cancer | sensitive | Pembrolizumab | Pembrolizumab | Guideline | Actionable | Keytruda (pembrolizumab) is included in guidelines as neoadjuvant and adjuvant (category 2A) and first-line therapy (category 1) for patients with CD274 (PD-L1)-positive (CPS >= 1) recurrent, unresectable, or metastatic oropharynx cancer (NCCN.org). | detail... |
| CD274 positive | hypopharynx cancer | sensitive | Pembrolizumab | Pembrolizumab | Guideline | Actionable | Keytruda (pembrolizumab) is included in guidelines as neoadjuvant and adjuvant (category 2A) and first-line therapy (category 1) for patients with CD274 (PD-L1)-positive (CPS >= 1) recurrent, unresectable, or metastatic hypopharynx cancer (NCCN.org). | detail... |
| CD274 positive | glottis cancer | sensitive | Pembrolizumab | Pembrolizumab | Guideline | Actionable | Keytruda (pembrolizumab) is included in guidelines as neoadjuvant and adjuvant (category 2A)and first-line therapy for patients with CD274 (PD-L1)-positive (CPS >= 1) recurrent, unresectable, or metastatic glottic larynx cancer (NCCN.org). | detail... |
| CD274 positive | supraglottis cancer | sensitive | Pembrolizumab | Pembrolizumab | Guideline | Actionable | Keytruda (pembrolizumab) is included in guidelines as neoadjuvant and adjuvant (category 2A) and first-line therapy (category 1) for patients with CD274 (PD-L1)-positive (CPS >= 1) recurrent, unresectable, or metastatic supraglottic larynx cancer (NCCN.org). | detail... |
| CD274 positive | ethmoid sinus cancer | sensitive | Pembrolizumab | Pembrolizumab | Guideline | Actionable | Keytruda (pembrolizumab) is included in guidelines as first-line therapy (category 1) for patients with CD274 (PD-L1)-positive (CPS >= 1) recurrent, unresectable, or metastatic ethmoid sinus cancer (NCCN.org). | detail... |
| CD274 positive | maxillary sinus cancer | sensitive | Pembrolizumab | Pembrolizumab | Guideline | Actionable | Keytruda (pembrolizumab) is included in guidelines as first-line therapy (category 1) for patients with CD274 (PD-L1)-positive (CPS >= 1) recurrent, unresectable, or metastatic maxillary sinus cancer (NCCN.org). | detail... |
| CD274 positive | oral cavity cancer | sensitive | Ipilimumab + Nivolumab | Ipilimumab + Nivolumab | Guideline | Actionable | Opdivo (nivolumab) in combination with Yervoy (ipilimumab) is included in guidelines as first-line therapy (category 2B) for patients with CD274 (PD-L1)-positive (CPS >= 20) recurrent, unresectable, or metastatic oral cavity cancer (NCCN.org). | detail... |
| CD274 positive | oropharynx cancer | sensitive | Ipilimumab + Nivolumab | Ipilimumab + Nivolumab | Guideline | Actionable | Opdivo (nivolumab) in combination with Yervoy (ipilimumab) is included in guidelines as first-line therapy (category 2B) for patients with CD274 (PD-L1)-positive (CPS >= 20) recurrent, unresectable, or metastatic oropharynx cancer (NCCN.org). | detail... |
| CD274 positive | hypopharynx cancer | sensitive | Ipilimumab + Nivolumab | Ipilimumab + Nivolumab | Guideline | Actionable | Opdivo (nivolumab) in combination with Yervoy (ipilimumab) is included in guidelines as first-line therapy (category 2B) for patients with CD274 (PD-L1)-positive (CPS >= 20) recurrent, unresectable, or metastatic hypopharynx cancer (NCCN.org). | detail... |
| CD274 positive | glottis cancer | sensitive | Ipilimumab + Nivolumab | Ipilimumab + Nivolumab | Guideline | Actionable | Opdivo (nivolumab) in combination with Yervoy (ipilimumab) is included in guidelines as first-line therapy (category 2B) for patients with CD274 (PD-L1)-positive (CPS >= 20) recurrent, unresectable, or metastatic glottic larynx cancer (NCCN.org). | detail... |
| CD274 positive | supraglottis cancer | sensitive | Ipilimumab + Nivolumab | Ipilimumab + Nivolumab | Guideline | Actionable | Opdivo (nivolumab) in combination with Yervoy (ipilimumab) is included in guidelines as first-line therapy (category 2B) for patients with CD274 (PD-L1)-positive (CPS >= 20) recurrent, unresectable, or metastatic supraglottic larynx cancer (NCCN.org). | detail... |
| CD274 positive | ethmoid sinus cancer | sensitive | Ipilimumab + Nivolumab | Ipilimumab + Nivolumab | Guideline | Actionable | Opdivo (nivolumab) in combination with Yervoy (ipilimumab) is included in guidelines as first-line therapy (category 2B) for patients with CD274 (PD-L1)-positive (CPS >= 20) recurrent, unresectable, or metastatic ethmoid sinus cancer (NCCN.org). | detail... |
| CD274 positive | maxillary sinus cancer | sensitive | Ipilimumab + Nivolumab | Ipilimumab + Nivolumab | Guideline | Actionable | Opdivo (nivolumab) in combination with Yervoy (ipilimumab) is included in guidelines as first-line therapy (category 2B) for patients with CD274 (PD-L1)-positive (CPS >= 20) recurrent, unresectable, or metastatic maxillary sinus cancer (NCCN.org). | detail... |
| CD274 positive | esophagus squamous cell carcinoma | sensitive | Tislelizumab | Guideline | Actionable | Tevimbra (tislelizumab) in combination with chemotherapy is included in guidelines as first-line therapy for patients with advanced esophageal squamous carcinoma expressing CD274 (PD-L1, TAP >/= 5%) (PMID: 39986705; ESMO.org). | 39986705 detail... | |
| CD274 positive | stomach cancer | sensitive | Nivolumab | Guideline | Actionable | Opdivo (nivolumab) in combination with platinum and fluoropyrimidine-based chemotherapy is included in the Pan-Asian Guidelines Adaptation (PAGA) as first-line therapy for patients with advanced untreated gastric cancer with a CD274 (PD-L1) expression of CPS >/=5 (PMID: 38458658; ESMO.org). | 38458658 detail... | |
| CD274 positive | esophageal cancer | sensitive | Nivolumab | Guideline | Actionable | Opdivo (nivolumab) in combination with platinum and fluoropyrimidine-based chemotherapy is included in the Pan-Asian Guidelines Adaptation (PAGA) as first-line therapy for patients with advanced untreated esophageal cancer with a CD274 (PD-L1) expression of CPS >/=5 (PMID: 38458658; ESMO.org). | 38458658 detail... | |
| CD274 positive | gastroesophageal junction adenocarcinoma | sensitive | Nivolumab | Guideline | Actionable | Opdivo (nivolumab) in combination with platinum and fluoropyrimidine-based chemotherapy is included in the Pan-Asian Guidelines Adaptation (PAGA) as first-line therapy for patients with advanced untreated gastroesophageal junction cancer with a CD274 (PD-L1) expression of CPS >/=5 (PMID: 38458658; ESMO.org). | detail... 38458658 | |
| CD274 positive | gastroesophageal junction adenocarcinoma | sensitive | Pembrolizumab | Pembrolizumab | Guideline | Actionable | Keytruda (pembrolizumab) in combination with platinum and fluoropyrimidine-based chemotherapy is included in the Pan-Asian Guidelines Adaptation (PAGA) as first-line therapy for patients with ERBB2 (HER2)-negative, metastatic gastroesophageal junction cancer with CD274 (PD-L1) expression, especially for those with higher levels of tumor CD274 (PD-L1) expression (PMID: 38458658; ESMO.org). | detail... 38458658 |
| CD274 positive | stomach cancer | sensitive | Pembrolizumab | Pembrolizumab | Guideline | Actionable | Keytruda (pembrolizumab) in combination with platinum and fluoropyrimidine-based chemotherapy is included in the Pan-Asian Guidelines Adaptation (PAGA) as first-line therapy for patients with ERBB2 (HER2)-negative, metastatic gastric cancer with CD274 (PD-L1) expression, especially for those with higher levels of tumor CD274 (PD-L1) expression (PMID: 38458658; ESMO.org). | detail... 38458658 |
| CD274 positive | stomach cancer | sensitive | Capecitabine + Cisplatin + Pembrolizumab | Guideline | Actionable | Keytruda (pembrolizumab) in combination with Xeloda (capecitabine) and Platinol (cisplatin) is included in guidelines as a preferred first-line therapy for patients with locally advanced, recurrent, or metastatic gastric cancer expressing CD274 (PD-L1) with CPS >/= 1 (category 1 for CPS >/= 5) and without ERBB2 (HER2) overexpression (NCCN.org). | detail... | |
| CD274 positive | stomach cancer | sensitive | Cisplatin + Fluorouracil + Pembrolizumab | Guideline | Actionable | Keytruda (pembrolizumab) in combination with Adrucil (fluorouracil) and Platinol (cisplatin) is included in guidelines as a preferred first-line therapy for patients with locally advanced, recurrent, or metastatic gastric cancer expressing CD274 (PD-L1) with CPS >/= 1 (category 1 for CPS >/= 5) and without ERBB2 (HER2) overexpression (NCCN.org). | detail... | |
| CD274 positive | esophagus squamous cell carcinoma | sensitive | Ipilimumab + Nivolumab | Ipilimumab + Nivolumab | Guideline | Actionable | Opdivo (nivolumab) in combination with Yervoy (ipilimumab) is included in guidelines as first-line therapy (category 2A) for patients with CD274 (PD-L1)-positive (CPS >= 1) recurrent, unresectable, or metastatic esophagus squamous cell carcinoma (NCCN.org). | detail... |
| CD274 positive | cervical cancer | sensitive | Bevacizumab + Cisplatin + Paclitaxel + Pembrolizumab | Guideline | Actionable | Keytruda (pembrolizumab) combined with Taxol (paclitaxel), Platinol (cisplatin), and Avastin (bevacizumab) is included in guidelines as first-line therapy for patients with CD274 (PD-L1)-positive cervical cancer (NCCN.org). | detail... | |
| CD274 positive | cervical cancer | sensitive | Cisplatin + Paclitaxel + Pembrolizumab | Guideline | Actionable | Keytruda (pembrolizumab) combined with Platinol (cisplatin) and Taxol (paclitaxel) is included in guidelines as first-line therapy for patients with CD274 (PD-L1)-positive cervical cancer (NCCN.org). | detail... | |
| CD274 positive | cervical cancer | sensitive | Bevacizumab + Carboplatin + Paclitaxel + Pembrolizumab | Guideline | Actionable | Keytruda (pembrolizumab) combined with Taxol (paclitaxel), Paraplatin (carboplatin), and Avastin (bevacizumab) is included in guidelines as first-line therapy for patients with CD274 (PD-L1)-positive cervical cancer (NCCN.org). | detail... | |
| CD274 positive | cervical cancer | sensitive | Carboplatin + Paclitaxel + Pembrolizumab | Guideline | Actionable | Keytruda (pembrolizumab) combined with Taxol (paclitaxel) and Paraplatin (carboplatin) is included in guidelines as first-line therapy for patients with CD274 (PD-L1)-positive cervical cancer (NCCN.org). | detail... | |
| CD274 positive | estrogen-receptor positive breast cancer | predicted - sensitive | Anthracycline + Cyclophosphamide + Nivolumab + Paclitaxel | Phase III | Actionable | In a Phase III trial (CheckMate 7FL), the addition of Opdivo (nivolumab) to neoadjuvant chemotherapy with Taxol (paclitaxel) for 12 weeks followed by Opdivo (nivolumab) plus Cytoxan (cyclophosphamide) and Anthracycline resulted in improved pathologic complete response rate (44.3% vs 20.2%) compared to placebo plus neoadjuvant chemotherapy in patients with high-risk, early stage, ER (ESR1)-positive, CD274 (PD-L1)-positive (CPS>=1%), ERBB2 (HER2)-negative breast cancer (PMID: 39838118; NCT04109066). | 39838118 | |
| CD274 positive | gastroesophageal junction adenocarcinoma | predicted - sensitive | Cadonilimab + Capecitabine + Oxaliplatin | Phase III | Actionable | In a Phase III trial (COMPASSION-15), first-line combination therapy with Cadonilimab, Xeloda (capecitabine), and Eloxatin (oxaliplatin) demonstrated safety in CD274 (PD-L1)-positive (CPS >=5), ERBB2 (HER2)-negative gastric or gastroesophageal junction adenocarcinoma patients, and resulted in an improved median overall survival (15.3 vs 10.9 mo, HR=0.58) and median progression-free survival (6.9 vs 5.5 mo, HR=0.51) compared to placebo plus chemotherapy (PMID: 39843940; NCT05008783). | 39843940 | |
| CD274 positive | gastric adenocarcinoma | predicted - sensitive | Cadonilimab + Capecitabine + Oxaliplatin | Phase III | Actionable | In a Phase III trial (COMPASSION-15), first-line combination therapy with Cadonilimab, Xeloda (capecitabine), and Eloxatin (oxaliplatin) demonstrated safety in CD274 (PD-L1)-positive (CPS >=5), ERBB2 (HER2)-negative gastric or gastroesophageal junction adenocarcinoma patients, and resulted in an improved median overall survival (15.3 vs 10.9 mo, HR=0.58) and median progression-free survival (6.9 vs 5.5 mo, HR=0.51) compared to placebo plus chemotherapy (PMID: 39843940; NCT05008783). | 39843940 | |
| CD274 positive | stomach cancer | sensitive | Capecitabine + Oxaliplatin + Pembrolizumab | Guideline | Actionable | Keytruda (pembrolizumab) in combination with Xeloda (capecitabine) and Eloxatin (oxaliplatin) is included in guidelines as a preferred first-line therapy for patients with locally advanced, recurrent, or metastatic gastric cancer expressing CD274 (PD-L1) with CPS >/= 1 (category 1 for CPS >/= 5) and without ERBB2 (HER2) overexpression (NCCN.org). | detail... | |
| CD274 positive | stomach cancer | sensitive | Fluorouracil + Oxaliplatin + Pembrolizumab | Guideline | Actionable | Keytruda (pembrolizumab) in combination with Adrucil (fluorouracil) and Eloxatin (oxaliplatin) is included in guidelines as a preferred first-line therapy for patients with locally advanced, recurrent, or metastatic gastric cancer expressing CD274 (PD-L1) with CPS >/= 1 (category 1 for CPS >/= 5) and without ERBB2 (HER2) overexpression (NCCN.org). | detail... | |
| CD274 positive | stomach cancer | sensitive | Fluorouracil + Nivolumab + Oxaliplatin | Guideline | Actionable | Opdivo (nivolumab) in combination with Adrucil (fluorouracil) and Eloxatin (oxaliplatin) is included in guidelines as a preferred first-line therapy for patients with locally advanced, recurrent, or metastatic gastric cancer expressing CD274 (PD-L1) with CPS >/= 1 (category 1 for CPS >/= 5) and without ERBB2 (HER2) overexpression (NCCN.org). | detail... | |
| CD274 positive | stomach cancer | sensitive | Capecitabine + Nivolumab + Oxaliplatin | Guideline | Actionable | Opdivo (nivolumab) in combination with Xeloda (capecitabine) and Eloxatin (oxaliplatin) is included in guidelines as a preferred first-line therapy for patients with locally advanced, recurrent, or metastatic gastric cancer expressing CD274 (PD-L1) with CPS >/= 1 (category 1 for CPS >/= 5) and without ERBB2 (HER2) overexpression (NCCN.org). | detail... | |
| CD274 positive | stomach cancer | sensitive | Fluorouracil + Oxaliplatin + Tislelizumab | Guideline | Actionable | Tevimbra (tislelizumab) in combination with Adrucil (fluorouracil) and Eloxatin (oxaliplatin) is included in guidelines as a preferred first-line therapy for patients with locally advanced, recurrent, or metastatic gastric cancer expressing CD274 (PD-L1) with CPS >/= 1 (category 1 for CPS >/= 5) and without ERBB2 (HER2) overexpression (NCCN.org). | detail... | |
| CD274 positive | stomach cancer | sensitive | Cisplatin + Fluorouracil + Tislelizumab | Guideline | Actionable | Tevimbra (tislelizumab) in combination with Adrucil (fluorouracil) and Platinol (cisplatin) is included in guidelines as a preferred first-line therapy for patients with locally advanced, recurrent, or metastatic gastric cancer expressing CD274 (PD-L1) with CPS >/= 1 (category 1 for CPS >/= 5) and without ERBB2 (HER2) overexpression (NCCN.org). | detail... | |
| CD274 positive | stomach cancer | sensitive | Capecitabine + Cisplatin + Tislelizumab | Guideline | Actionable | Tevimbra (tislelizumab) in combination with Xeloda (capecitabine) and Platinol (cisplatin) is included in guidelines as a preferred first-line therapy for patients with locally advanced, recurrent, or metastatic gastric cancer expressing CD274 (PD-L1) with CPS >/= 1 (category 1 for CPS >/= 5) and without ERBB2 (HER2) overexpression (NCCN.org). | detail... | |
| CD274 positive | stomach cancer | sensitive | Capecitabine + Oxaliplatin + Tislelizumab | Guideline | Actionable | Tevimbra (tislelizumab) in combination with Xeloda (capecitabine) and Eloxatin (oxaliplatin) is included in guidelines as a preferred first-line therapy for patients with locally advanced, recurrent, or metastatic gastric cancer expressing CD274 (PD-L1) with CPS >/= 1 (category 1 for CPS >/= 5) and without ERBB2 (HER2) overexpression (NCCN.org). | detail... | |
| CD274 positive | esophagus squamous cell carcinoma | sensitive | Fluorouracil + Nivolumab + Oxaliplatin | Guideline | Actionable | Opdivo (nivolumab) in combination with first-line chemotherapy including Adrucil (fluorouracil) and Eloxatin (oxaliplatin) is included in guidelines as preferred first-line therapy for patients with locally advanced, recurrent, or metastatic ERBB2 (HER2) overexpression negative esophageal squamous cell carcinoma expressing PD-L1 (CD274) with CPS >/= 1 (category 1) (NCCN.org). | detail... | |
| CD274 positive | esophagus squamous cell carcinoma | sensitive | Capecitabine + Nivolumab + Oxaliplatin | Guideline | Actionable | Opdivo (nivolumab) in combination with first-line chemotherapy including Xeloda (capecitabine) and Eloxatin (oxaliplatin) is included in guidelines as preferred first-line therapy for patients with locally advanced, recurrent, or metastatic ERBB2 (HER2) overexpression negative esophageal squamous cell carcinoma expressing PD-L1 (CD274) with CPS >/= 1 (category 1) (NCCN.org). | detail... | |
| CD274 positive | esophagus squamous cell carcinoma | sensitive | Cisplatin + Fluorouracil + Nivolumab | Guideline | Actionable | Opdivo (nivolumab) in combination with first-line chemotherapy including Adrucil (fluorouracil) and Platinol (cisplatin) is included in guidelines as preferred first-line therapy for patients with locally advanced, recurrent, or metastatic ERBB2 (HER2) overexpression negative esophageal squamous cell carcinoma expressing PD-L1 (CD274) with CPS >/= 1 (category 1) (NCCN.org). | detail... | |
| CD274 positive | esophagus squamous cell carcinoma | sensitive | Capecitabine + Cisplatin + Nivolumab | Guideline | Actionable | Opdivo (nivolumab) in combination with first-line chemotherapy including Xeloda (capecitabine) and Platinol (cisplatin) is included in guidelines as preferred first-line therapy for patients with locally advanced, recurrent, or metastatic ERBB2 (HER2) overexpression negative esophageal squamous cell carcinoma expressing PD-L1 (CD274) with CPS >/= 1 (category 1) (NCCN.org). | detail... | |
| CD274 positive | head and neck squamous cell carcinoma | sensitive | Pembrolizumab | Pembrolizumab | FDA approved - On Companion Diagnostic | Actionable | In a Phase III trial (KEYNOTE-689) that supported FDA approval, neoadjuvant and adjuvant Keytruda (pembrolizumab) plus standard of case (SOC) significantly improved event-free survival compared to SOC (59.7 vs 29.6 months, HR=0.70, p=0.00140) and major pathological response rate difference (9.8%, p<0.00001) in patients with CD274 (PD-L1)-positive (CPS >=1) resectable locally advanced head and neck squamous cell carcinoma (PMID: 40532178; NCT03765918). | detail... 40532178 detail... |
| CD274 positive | lung non-small cell carcinoma | predicted - sensitive | Pembrolizumab + SGN-B6A | Phase I | Actionable | In a Phase I trial (SGNB6A-001), SGN-B6A and Keytruda (pembrolizumab) combination treatment demonstrated safety and activity in patients with CD274 (PD-L1)-positive (CPS >=1) non-small cell lung cancer, resulting in an overall response rate of 57% (4/7) with 1 confirmed complete response, 1 confirmed partial response, and 2 partial responses pending confirmation (J Clin Oncol 2025 43: 16_suppl, 3122; NCT04389632). | detail... | |
| CD274 positive | head and neck squamous cell carcinoma | predicted - sensitive | Pembrolizumab + SGN-B6A | Phase I | Actionable | In a Phase I trial (SGNB6A-001), SGN-B6A and Keytruda (pembrolizumab) combination treatment demonstrated safety and activity in patients with CD274 (PD-L1)-positive (CPS >=1) head and neck squamous cell carcinoma, resulting in a confirmed overall response rate of 37.5% (3/8) with 2 confirmed complete response and 1 confirmed partial response (J Clin Oncol 2025 43: 16_suppl, 3122; NCT04389632). | detail... | |
| CD274 positive | lung squamous cell carcinoma | sensitive | Carboplatin + Durvalumab + Gemcitabine + Tremelimumab | Guideline | Actionable | Combination Paraplatin (carboplatin), Gemzar (gemcitabine), Imfinzi (durvalumab), and Imjudo (tremelimumab) is included in guidelines as first-line therapy for advanced or metastatic lung squamous cell carcinoma patients with CD274 (PD-L1) expression of 1% to 49%, and negative for actionable molecular biomarkers (NCCN.org). | detail... | |
| CD274 positive | lung squamous cell carcinoma | sensitive | Carboplatin + Durvalumab + Nab-paclitaxel + Tremelimumab | Guideline | Actionable | Combination Paraplatin (carboplatin), Abraxane (nab-paclitaxel), Imfinzi (durvalumab), and Imjudo (tremelimumab) is in guidelines as first-line therapy for patients with advanced or metastatic lung squamous cell carcinoma, with CD274 (PD-L1) expression of 1% to 49%, and negative for actionable molecular biomarkers (NCCN.org). | detail... | |
| CD274 positive | lung squamous cell carcinoma | sensitive | Cisplatin + Durvalumab + Gemcitabine + Tremelimumab | Guideline | Actionable | Combination Platinol (cisplatin), Gemzar (gemcitabine), Imfinzi (durvalumab), and Imjudo (tremelimumab) is included in guidelines as first-line therapy for advanced or metastatic lung squamous cell carcinoma patients with CD274 (PD-L1) expression of 1% to 49%, and negative for actionable molecular biomarkers (NCCN.org). | detail... | |
| CD274 positive | gastroesophageal junction adenocarcinoma | sensitive | Docetaxel + Durvalumab + Fluorouracil + Leucovorin + Oxaliplatin | Guideline | Actionable | Imfinzi (durvalumab) in combination with FLOT (fluorouracil, leucovorin, oxaliplatin, docetaxel) is included in guidelines as preferred perioperative systemic therapy (category 1) for patients with gastroesophageal junction adenocarcinoma expressing CD274 (PD-L1) (CPS>/=1 or TAP>/=1%) (NCCN.org). | detail... | |
| CD274 positive | esophagus adenocarcinoma | sensitive | Docetaxel + Durvalumab + Fluorouracil + Leucovorin + Oxaliplatin | Guideline | Actionable | Imfinzi (durvalumab) in combination with FLOT (fluorouracil, leucovorin, oxaliplatin, docetaxel) is included in guidelines as preferred perioperative systemic therapy for patients with esophageal adenocarcinoma expressing CD274 (PD-L1) (CPS>/=1 or TAP>/=1%) (NCCN.org). | detail... | |
| CD274 positive | esophagus squamous cell carcinoma | sensitive | Fluorouracil + Oxaliplatin + Tislelizumab | Guideline | Actionable | Tevimbra (tislelizumab) in combination with Adrucil (fluorouracil) and Eloxatin (oxaliplatin) is included in guidelines as preferred systemic therapy (category 1) for patients with unresectable locally advanced, recurrent, or metastatic esophageal squamous cell carcinoma expressing PD-L1 (CD274) with CPS >/= 1 (NCCN.org). | detail... | |
| CD274 positive | esophagus squamous cell carcinoma | sensitive | Capecitabine + Oxaliplatin + Tislelizumab | Guideline | Actionable | Tevimbra (tislelizumab) in combination with Xeloda (capecitabine) and Eloxatin (oxaliplatin) is included in guidelines as preferred systemic therapy (category 1) for patients with unresectable locally advanced, recurrent, or metastatic esophageal squamous cell carcinoma expressing PD-L1 (CD274) with CPS >/= 1 (NCCN.org). | detail... | |
| CD274 positive | esophagus squamous cell carcinoma | sensitive | Oxaliplatin + Paclitaxel + Tislelizumab | Guideline | Actionable | Tevimbra (tislelizumab) in combination with Taxol (paclitaxel) and Eloxatin (oxaliplatin) is included in guidelines as preferred systemic therapy for patients with unresectable locally advanced, recurrent, or metastatic esophageal squamous cell carcinoma expressing PD-L1 (CD274) with CPS >/= 1 (NCCN.org). | detail... | |
| CD274 positive | esophagus squamous cell carcinoma | sensitive | Cisplatin + Paclitaxel + Tislelizumab | Guideline | Actionable | Tevimbra (tislelizumab) in combination with Taxol (paclitaxel) and Platinol (cisplatin) is included in guidelines as preferred systemic therapy for patients with unresectable locally advanced, recurrent, or metastatic esophageal squamous cell carcinoma expressing PD-L1 (CD274) with CPS >/= 1 (NCCN.org). | detail... | |
| CD274 positive | esophagus squamous cell carcinoma | sensitive | Capecitabine + Cisplatin + Tislelizumab | Guideline | Actionable | Tevimbra (tislelizumab) in combination with Xeloda (capecitabine) and Platinol (cisplatin) is included in guidelines as preferred systemic therapy (category 1) for patients with unresectable locally advanced, recurrent, or metastatic esophageal squamous cell carcinoma expressing PD-L1 (CD274) with CPS >/= 1 (NCCN.org). | detail... | |
| CD274 positive | esophagus squamous cell carcinoma | sensitive | Cisplatin + Fluorouracil + Tislelizumab | Guideline | Actionable | Tevimbra (tislelizumab) in combination with Adrucil (fluorouracil) and Platinol (cisplatin) is included in guidelines as preferred systemic therapy (category 1) for patients with unresectable locally advanced, recurrent, or metastatic esophageal squamous cell carcinoma expressing PD-L1 (CD274) with CPS >/= 1 (NCCN.org). | detail... | |
| CD274 positive | vaginal carcinoma | sensitive | Bevacizumab + Carboplatin + Paclitaxel + Pembrolizumab | Guideline | Actionable | Keytruda (pembrolizumab) in combination with Paraplatin (carboplatin), Taxol (paclitaxel), and Avastin (bevacizumab) is included in guidelines as preferred first-line therapy for patients with recurrent or metastatic vaginal squamous cell carcinoma or adenocarcinoma with CD274 (PD-L1) expression (CPS >/= 1) (NCCN.org). | detail... |